Deprecated (16384): The ArrayAccess methods will be removed in 4.0.0.Use getParam(), getData() and getQuery() instead. - /home/brlfuser/public_html/src/Controller/ArtileDetailController.php, line: 73
 You can disable deprecation warnings by setting `Error.errorLevel` to `E_ALL & ~E_USER_DEPRECATED` in your config/app.php. [CORE/src/Core/functions.php, line 311]
Code Context


        trigger_error($message, E_USER_DEPRECATED);

    }
$message = 'The ArrayAccess methods will be removed in 4.0.0.Use getParam(), getData() and getQuery() instead. - /home/brlfuser/public_html/src/Controller/ArtileDetailController.php, line: 73
 You can disable deprecation warnings by setting `Error.errorLevel` to `E_ALL & ~E_USER_DEPRECATED` in your config/app.php.'
$stackFrame = (int) 1
$trace = [
	(int) 0 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/ServerRequest.php',
		'line' => (int) 2421,
		'function' => 'deprecationWarning',
		'args' => [
			(int) 0 => 'The ArrayAccess methods will be removed in 4.0.0.Use getParam(), getData() and getQuery() instead.'
		]
	],
	(int) 1 => [
		'file' => '/home/brlfuser/public_html/src/Controller/ArtileDetailController.php',
		'line' => (int) 73,
		'function' => 'offsetGet',
		'class' => 'Cake\Http\ServerRequest',
		'object' => object(Cake\Http\ServerRequest) {},
		'type' => '->',
		'args' => [
			(int) 0 => 'catslug'
		]
	],
	(int) 2 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Controller/Controller.php',
		'line' => (int) 610,
		'function' => 'printArticle',
		'class' => 'App\Controller\ArtileDetailController',
		'object' => object(App\Controller\ArtileDetailController) {},
		'type' => '->',
		'args' => []
	],
	(int) 3 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/ActionDispatcher.php',
		'line' => (int) 120,
		'function' => 'invokeAction',
		'class' => 'Cake\Controller\Controller',
		'object' => object(App\Controller\ArtileDetailController) {},
		'type' => '->',
		'args' => []
	],
	(int) 4 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/ActionDispatcher.php',
		'line' => (int) 94,
		'function' => '_invoke',
		'class' => 'Cake\Http\ActionDispatcher',
		'object' => object(Cake\Http\ActionDispatcher) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(App\Controller\ArtileDetailController) {}
		]
	],
	(int) 5 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/BaseApplication.php',
		'line' => (int) 235,
		'function' => 'dispatch',
		'class' => 'Cake\Http\ActionDispatcher',
		'object' => object(Cake\Http\ActionDispatcher) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 6 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Http\BaseApplication',
		'object' => object(App\Application) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 7 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Routing/Middleware/RoutingMiddleware.php',
		'line' => (int) 162,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 8 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Routing\Middleware\RoutingMiddleware',
		'object' => object(Cake\Routing\Middleware\RoutingMiddleware) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 9 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Routing/Middleware/AssetMiddleware.php',
		'line' => (int) 88,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 10 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Routing\Middleware\AssetMiddleware',
		'object' => object(Cake\Routing\Middleware\AssetMiddleware) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 11 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Middleware/ErrorHandlerMiddleware.php',
		'line' => (int) 96,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 12 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Error\Middleware\ErrorHandlerMiddleware',
		'object' => object(Cake\Error\Middleware\ErrorHandlerMiddleware) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 13 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 51,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 14 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Server.php',
		'line' => (int) 98,
		'function' => 'run',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\MiddlewareQueue) {},
			(int) 1 => object(Cake\Http\ServerRequest) {},
			(int) 2 => object(Cake\Http\Response) {}
		]
	],
	(int) 15 => [
		'file' => '/home/brlfuser/public_html/webroot/index.php',
		'line' => (int) 39,
		'function' => 'run',
		'class' => 'Cake\Http\Server',
		'object' => object(Cake\Http\Server) {},
		'type' => '->',
		'args' => []
	]
]
$frame = [
	'file' => '/home/brlfuser/public_html/src/Controller/ArtileDetailController.php',
	'line' => (int) 73,
	'function' => 'offsetGet',
	'class' => 'Cake\Http\ServerRequest',
	'object' => object(Cake\Http\ServerRequest) {
		trustProxy => false
		[protected] params => [
			[maximum depth reached]
		]
		[protected] data => [[maximum depth reached]]
		[protected] query => [[maximum depth reached]]
		[protected] cookies => [
			[maximum depth reached]
		]
		[protected] _environment => [
			[maximum depth reached]
		]
		[protected] url => 'latest-news-updates/soon-cancer-medicines-stents-to-be-cheaper-sushmi-dey-4677264/print'
		[protected] base => ''
		[protected] webroot => '/'
		[protected] here => '/latest-news-updates/soon-cancer-medicines-stents-to-be-cheaper-sushmi-dey-4677264/print'
		[protected] trustedProxies => [[maximum depth reached]]
		[protected] _input => null
		[protected] _detectors => [
			[maximum depth reached]
		]
		[protected] _detectorCache => [
			[maximum depth reached]
		]
		[protected] stream => object(Zend\Diactoros\PhpInputStream) {}
		[protected] uri => object(Zend\Diactoros\Uri) {}
		[protected] session => object(Cake\Http\Session) {}
		[protected] attributes => [[maximum depth reached]]
		[protected] emulatedAttributes => [
			[maximum depth reached]
		]
		[protected] uploadedFiles => [[maximum depth reached]]
		[protected] protocol => null
		[protected] requestTarget => null
		[private] deprecatedProperties => [
			[maximum depth reached]
		]
	},
	'type' => '->',
	'args' => [
		(int) 0 => 'catslug'
	]
]
deprecationWarning - CORE/src/Core/functions.php, line 311
Cake\Http\ServerRequest::offsetGet() - CORE/src/Http/ServerRequest.php, line 2421
App\Controller\ArtileDetailController::printArticle() - APP/Controller/ArtileDetailController.php, line 73
Cake\Controller\Controller::invokeAction() - CORE/src/Controller/Controller.php, line 610
Cake\Http\ActionDispatcher::_invoke() - CORE/src/Http/ActionDispatcher.php, line 120
Cake\Http\ActionDispatcher::dispatch() - CORE/src/Http/ActionDispatcher.php, line 94
Cake\Http\BaseApplication::__invoke() - CORE/src/Http/BaseApplication.php, line 235
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\RoutingMiddleware::__invoke() - CORE/src/Routing/Middleware/RoutingMiddleware.php, line 162
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\AssetMiddleware::__invoke() - CORE/src/Routing/Middleware/AssetMiddleware.php, line 88
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Error\Middleware\ErrorHandlerMiddleware::__invoke() - CORE/src/Error/Middleware/ErrorHandlerMiddleware.php, line 96
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Http\Runner::run() - CORE/src/Http/Runner.php, line 51
Cake\Http\Server::run() - CORE/src/Http/Server.php, line 98

Deprecated (16384): The ArrayAccess methods will be removed in 4.0.0.Use getParam(), getData() and getQuery() instead. - /home/brlfuser/public_html/src/Controller/ArtileDetailController.php, line: 74
 You can disable deprecation warnings by setting `Error.errorLevel` to `E_ALL & ~E_USER_DEPRECATED` in your config/app.php. [CORE/src/Core/functions.php, line 311]
Code Context


        trigger_error($message, E_USER_DEPRECATED);

    }
$message = 'The ArrayAccess methods will be removed in 4.0.0.Use getParam(), getData() and getQuery() instead. - /home/brlfuser/public_html/src/Controller/ArtileDetailController.php, line: 74
 You can disable deprecation warnings by setting `Error.errorLevel` to `E_ALL & ~E_USER_DEPRECATED` in your config/app.php.'
$stackFrame = (int) 1
$trace = [
	(int) 0 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/ServerRequest.php',
		'line' => (int) 2421,
		'function' => 'deprecationWarning',
		'args' => [
			(int) 0 => 'The ArrayAccess methods will be removed in 4.0.0.Use getParam(), getData() and getQuery() instead.'
		]
	],
	(int) 1 => [
		'file' => '/home/brlfuser/public_html/src/Controller/ArtileDetailController.php',
		'line' => (int) 74,
		'function' => 'offsetGet',
		'class' => 'Cake\Http\ServerRequest',
		'object' => object(Cake\Http\ServerRequest) {},
		'type' => '->',
		'args' => [
			(int) 0 => 'artileslug'
		]
	],
	(int) 2 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Controller/Controller.php',
		'line' => (int) 610,
		'function' => 'printArticle',
		'class' => 'App\Controller\ArtileDetailController',
		'object' => object(App\Controller\ArtileDetailController) {},
		'type' => '->',
		'args' => []
	],
	(int) 3 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/ActionDispatcher.php',
		'line' => (int) 120,
		'function' => 'invokeAction',
		'class' => 'Cake\Controller\Controller',
		'object' => object(App\Controller\ArtileDetailController) {},
		'type' => '->',
		'args' => []
	],
	(int) 4 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/ActionDispatcher.php',
		'line' => (int) 94,
		'function' => '_invoke',
		'class' => 'Cake\Http\ActionDispatcher',
		'object' => object(Cake\Http\ActionDispatcher) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(App\Controller\ArtileDetailController) {}
		]
	],
	(int) 5 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/BaseApplication.php',
		'line' => (int) 235,
		'function' => 'dispatch',
		'class' => 'Cake\Http\ActionDispatcher',
		'object' => object(Cake\Http\ActionDispatcher) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 6 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Http\BaseApplication',
		'object' => object(App\Application) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 7 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Routing/Middleware/RoutingMiddleware.php',
		'line' => (int) 162,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 8 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Routing\Middleware\RoutingMiddleware',
		'object' => object(Cake\Routing\Middleware\RoutingMiddleware) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 9 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Routing/Middleware/AssetMiddleware.php',
		'line' => (int) 88,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 10 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Routing\Middleware\AssetMiddleware',
		'object' => object(Cake\Routing\Middleware\AssetMiddleware) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 11 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Middleware/ErrorHandlerMiddleware.php',
		'line' => (int) 96,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 12 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Error\Middleware\ErrorHandlerMiddleware',
		'object' => object(Cake\Error\Middleware\ErrorHandlerMiddleware) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 13 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 51,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 14 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Server.php',
		'line' => (int) 98,
		'function' => 'run',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\MiddlewareQueue) {},
			(int) 1 => object(Cake\Http\ServerRequest) {},
			(int) 2 => object(Cake\Http\Response) {}
		]
	],
	(int) 15 => [
		'file' => '/home/brlfuser/public_html/webroot/index.php',
		'line' => (int) 39,
		'function' => 'run',
		'class' => 'Cake\Http\Server',
		'object' => object(Cake\Http\Server) {},
		'type' => '->',
		'args' => []
	]
]
$frame = [
	'file' => '/home/brlfuser/public_html/src/Controller/ArtileDetailController.php',
	'line' => (int) 74,
	'function' => 'offsetGet',
	'class' => 'Cake\Http\ServerRequest',
	'object' => object(Cake\Http\ServerRequest) {
		trustProxy => false
		[protected] params => [
			[maximum depth reached]
		]
		[protected] data => [[maximum depth reached]]
		[protected] query => [[maximum depth reached]]
		[protected] cookies => [
			[maximum depth reached]
		]
		[protected] _environment => [
			[maximum depth reached]
		]
		[protected] url => 'latest-news-updates/soon-cancer-medicines-stents-to-be-cheaper-sushmi-dey-4677264/print'
		[protected] base => ''
		[protected] webroot => '/'
		[protected] here => '/latest-news-updates/soon-cancer-medicines-stents-to-be-cheaper-sushmi-dey-4677264/print'
		[protected] trustedProxies => [[maximum depth reached]]
		[protected] _input => null
		[protected] _detectors => [
			[maximum depth reached]
		]
		[protected] _detectorCache => [
			[maximum depth reached]
		]
		[protected] stream => object(Zend\Diactoros\PhpInputStream) {}
		[protected] uri => object(Zend\Diactoros\Uri) {}
		[protected] session => object(Cake\Http\Session) {}
		[protected] attributes => [[maximum depth reached]]
		[protected] emulatedAttributes => [
			[maximum depth reached]
		]
		[protected] uploadedFiles => [[maximum depth reached]]
		[protected] protocol => null
		[protected] requestTarget => null
		[private] deprecatedProperties => [
			[maximum depth reached]
		]
	},
	'type' => '->',
	'args' => [
		(int) 0 => 'artileslug'
	]
]
deprecationWarning - CORE/src/Core/functions.php, line 311
Cake\Http\ServerRequest::offsetGet() - CORE/src/Http/ServerRequest.php, line 2421
App\Controller\ArtileDetailController::printArticle() - APP/Controller/ArtileDetailController.php, line 74
Cake\Controller\Controller::invokeAction() - CORE/src/Controller/Controller.php, line 610
Cake\Http\ActionDispatcher::_invoke() - CORE/src/Http/ActionDispatcher.php, line 120
Cake\Http\ActionDispatcher::dispatch() - CORE/src/Http/ActionDispatcher.php, line 94
Cake\Http\BaseApplication::__invoke() - CORE/src/Http/BaseApplication.php, line 235
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\RoutingMiddleware::__invoke() - CORE/src/Routing/Middleware/RoutingMiddleware.php, line 162
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\AssetMiddleware::__invoke() - CORE/src/Routing/Middleware/AssetMiddleware.php, line 88
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Error\Middleware\ErrorHandlerMiddleware::__invoke() - CORE/src/Error/Middleware/ErrorHandlerMiddleware.php, line 96
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Http\Runner::run() - CORE/src/Http/Runner.php, line 51
Cake\Http\Server::run() - CORE/src/Http/Server.php, line 98

Warning (512): Unable to emit headers. Headers sent in file=/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Debugger.php line=853 [CORE/src/Http/ResponseEmitter.php, line 48]
Code Context
            if (Configure::read('debug')) {

                trigger_error($message, E_USER_WARNING);

            } else {
$response = object(Cake\Http\Response) {

	'status' => (int) 200,
	'contentType' => 'text/html',
	'headers' => [
		'Content-Type' => [
			[maximum depth reached]
		]
	],
	'file' => null,
	'fileRange' => [],
	'cookies' => object(Cake\Http\Cookie\CookieCollection) {},
	'cacheDirectives' => [],
	'body' => '<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN"
        "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml">
<head>
    <link rel="canonical" href="https://im4change.in/<pre class="cake-error"><a href="javascript:void(0);" onclick="document.getElementById('cakeErr67fe7e3ca7549-trace').style.display = (document.getElementById('cakeErr67fe7e3ca7549-trace').style.display == 'none' ? '' : 'none');"><b>Notice</b> (8)</a>: Undefined variable: urlPrefix [<b>APP/Template/Layout/printlayout.ctp</b>, line <b>8</b>]<div id="cakeErr67fe7e3ca7549-trace" class="cake-stack-trace" style="display: none;"><a href="javascript:void(0);" onclick="document.getElementById('cakeErr67fe7e3ca7549-code').style.display = (document.getElementById('cakeErr67fe7e3ca7549-code').style.display == 'none' ? '' : 'none')">Code</a> <a href="javascript:void(0);" onclick="document.getElementById('cakeErr67fe7e3ca7549-context').style.display = (document.getElementById('cakeErr67fe7e3ca7549-context').style.display == 'none' ? '' : 'none')">Context</a><pre id="cakeErr67fe7e3ca7549-code" class="cake-code-dump" style="display: none;"><code><span style="color: #000000"><span style="color: #0000BB"></span><span style="color: #007700">&lt;</span><span style="color: #0000BB">head</span><span style="color: #007700">&gt;
</span></span></code>
<span class="code-highlight"><code><span style="color: #000000">&nbsp;&nbsp;&nbsp;&nbsp;&lt;link&nbsp;rel="canonical"&nbsp;href="<span style="color: #0000BB">&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">Configure</span><span style="color: #007700">::</span><span style="color: #0000BB">read</span><span style="color: #007700">(</span><span style="color: #DD0000">'SITE_URL'</span><span style="color: #007700">);&nbsp;</span><span style="color: #0000BB">?&gt;&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$urlPrefix</span><span style="color: #007700">;</span><span style="color: #0000BB">?&gt;&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$article_current</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">category</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">slug</span><span style="color: #007700">;&nbsp;</span><span style="color: #0000BB">?&gt;</span>/<span style="color: #0000BB">&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$article_current</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">seo_url</span><span style="color: #007700">;&nbsp;</span><span style="color: #0000BB">?&gt;</span>.html"/&gt;
</span></code></span>
<code><span style="color: #000000"><span style="color: #0000BB">&nbsp;&nbsp;&nbsp;&nbsp;</span><span style="color: #007700">&lt;</span><span style="color: #0000BB">meta&nbsp;http</span><span style="color: #007700">-</span><span style="color: #0000BB">equiv</span><span style="color: #007700">=</span><span style="color: #DD0000">"Content-Type"&nbsp;</span><span style="color: #0000BB">content</span><span style="color: #007700">=</span><span style="color: #DD0000">"text/html;&nbsp;charset=utf-8"</span><span style="color: #007700">/&gt;
</span></span></code></pre><pre id="cakeErr67fe7e3ca7549-context" class="cake-context" style="display: none;">$viewFile = &#039;/home/brlfuser/public_html/src/Template/Layout/printlayout.ctp&#039;
$dataForView = [
	&#039;article_current&#039; =&gt; object(App\Model\Entity\Article) {

		&#039;id&#039; =&gt; (int) 29209,
		&#039;title&#039; =&gt; &#039;Soon, cancer medicines, stents to be cheaper -Sushmi Dey&#039;,
		&#039;subheading&#039; =&gt; &#039;&#039;,
		&#039;description&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;
-The Times of India&lt;br /&gt;
&lt;br /&gt;
&lt;em&gt;NEW DELHI: &lt;/em&gt;Cancer medicines and stents may soon be available at a substantially lower price. The health ministry is working on a model to procure such drugs in bulk at a negotiated price and supply them to hospitals and consumers through its own retail system like &#039;Jan Aushadhi&#039; stores. .&lt;br /&gt;
&lt;br /&gt;
The idea is to bring down prices of expensive cancer drugs and stents while not putting pressure on margins of companies, a health ministry official told TOI. The government is in talks with pharmaceutical companies to implement the scheme.&lt;br /&gt;
&lt;br /&gt;
Currently, prices of only 51 cancer medicines are capped or regulated by the government. However, several oncologists, public health experts and even institutes like Tata Memorial Cancer Hospital have advocated bringing in more cancer drugs under price control as these medicines are extremely expensive and often out of reach of majority of patients.&lt;br /&gt;
&lt;br /&gt;
Following this, the health ministry had planned to bring in more cancer drugs and high-end medical devices like stents directly under price regulation, which would have meant capping their prices. However, the proposal faced strong opposition from the department of pharmaceuticals, which raised concerns about already squeezing margins of manufacturers and a threat to introduction of new drugs in the country.&lt;br /&gt;
&lt;br /&gt;
After the feedback, the health ministry decided to extend CGHS kind of mechanism to cancer medicines and stents for other consumers also, the official said.&lt;br /&gt;
&lt;br /&gt;
The new proposal is also likely to work in favour of the industry as not only their margins will be protected through bulk supplies but supplying at a negotiated price will also take care of the threat they face from compulsory licences whereby other ompanies are allowed to produce patented drugs in public interest.&lt;br /&gt;
&lt;br /&gt;
In past few years, several multinationals in India had to face a threat of compulsory licence after generic drug manufacturers claimed that they can make patented oncology and anti-retroviral medicines available at much lower prices. In fact, the first, and so far the only one, compulsory licence granted in India to Natco Pharma was also for a kidney cancer drug Nexavar, originally from Bayer.&lt;br /&gt;
&lt;br /&gt;
The second application by BDR Pharma seeking CL was also for Bristol-Myers Squibb&#039;s cancer drug Dasatinib. Though it was rejected by the Patent Office, a fresh application was subsequently submitted to the Centre under Section 92 of the Patents Act, which allows such licences to be issued under cases of national emergency. A decision is yet to be taken on the application.&lt;br /&gt;
&lt;br /&gt;
The latest health ministry&#039;s proposal is likely to get a final shape by end of this year.&lt;br /&gt;
&lt;br /&gt;
Currently, the government regulates a total of 348 medicine formulations, prices of which are fixed by the National Pharmaceutical Pricing Authority. Companies are free to price all other medicines but with an annual increase of only up to 10%. In case of stents, there is no price control. The government negotiates prices only for those supplied under CGHS.&lt;br /&gt;
&lt;br /&gt;
&lt;/div&gt;&#039;,
		&#039;credit_writer&#039; =&gt; &#039;The Times of India, 19 September, 2015, http://timesofindia.indiatimes.com/india/Soon-cancer-medicines-stents-to-be-cheaper/articleshow/49019942.cms&#039;,
		&#039;article_img&#039; =&gt; &#039;&#039;,
		&#039;article_img_thumb&#039; =&gt; &#039;&#039;,
		&#039;status&#039; =&gt; (int) 1,
		&#039;show_on_home&#039; =&gt; (int) 1,
		&#039;lang&#039; =&gt; &#039;EN&#039;,
		&#039;category_id&#039; =&gt; (int) 16,
		&#039;tag_keyword&#039; =&gt; &#039;&#039;,
		&#039;seo_url&#039; =&gt; &#039;soon-cancer-medicines-stents-to-be-cheaper-sushmi-dey-4677264&#039;,
		&#039;meta_title&#039; =&gt; null,
		&#039;meta_keywords&#039; =&gt; null,
		&#039;meta_description&#039; =&gt; null,
		&#039;noindex&#039; =&gt; (int) 0,
		&#039;publish_date&#039; =&gt; object(Cake\I18n\FrozenDate) {},
		&#039;most_visit_section_id&#039; =&gt; null,
		&#039;article_big_img&#039; =&gt; null,
		&#039;liveid&#039; =&gt; (int) 4677264,
		&#039;created&#039; =&gt; object(Cake\I18n\FrozenTime) {},
		&#039;modified&#039; =&gt; object(Cake\I18n\FrozenTime) {},
		&#039;edate&#039; =&gt; &#039;&#039;,
		&#039;tags&#039; =&gt; [
			[maximum depth reached]
		],
		&#039;category&#039; =&gt; object(App\Model\Entity\Category) {},
		&#039;[new]&#039; =&gt; false,
		&#039;[accessible]&#039; =&gt; [
			[maximum depth reached]
		],
		&#039;[dirty]&#039; =&gt; [[maximum depth reached]],
		&#039;[original]&#039; =&gt; [[maximum depth reached]],
		&#039;[virtual]&#039; =&gt; [[maximum depth reached]],
		&#039;[hasErrors]&#039; =&gt; false,
		&#039;[errors]&#039; =&gt; [[maximum depth reached]],
		&#039;[invalid]&#039; =&gt; [[maximum depth reached]],
		&#039;[repository]&#039; =&gt; &#039;Articles&#039;
	
	},
	&#039;articleid&#039; =&gt; (int) 29209,
	&#039;metaTitle&#039; =&gt; &#039;LATEST NEWS UPDATES | Soon, cancer medicines, stents to be cheaper -Sushmi Dey&#039;,
	&#039;metaKeywords&#039; =&gt; &#039;generic medicine,Compulsory license,Access to Health,Access to Healthcare,Access to Medicines,Cancer,medicines&#039;,
	&#039;metaDesc&#039; =&gt; &#039;
-The Times of India

NEW DELHI: Cancer medicines and stents may soon be available at a substantially lower price. The health ministry is working on a model to procure such drugs in bulk at a negotiated price and supply them to...&#039;,
	&#039;disp&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;-The Times of India&lt;br /&gt;&lt;br /&gt;&lt;em&gt;NEW DELHI: &lt;/em&gt;Cancer medicines and stents may soon be available at a substantially lower price. The health ministry is working on a model to procure such drugs in bulk at a negotiated price and supply them to hospitals and consumers through its own retail system like &#039;Jan Aushadhi&#039; stores. .&lt;br /&gt;&lt;br /&gt;The idea is to bring down prices of expensive cancer drugs and stents while not putting pressure on margins of companies, a health ministry official told TOI. The government is in talks with pharmaceutical companies to implement the scheme.&lt;br /&gt;&lt;br /&gt;Currently, prices of only 51 cancer medicines are capped or regulated by the government. However, several oncologists, public health experts and even institutes like Tata Memorial Cancer Hospital have advocated bringing in more cancer drugs under price control as these medicines are extremely expensive and often out of reach of majority of patients.&lt;br /&gt;&lt;br /&gt;Following this, the health ministry had planned to bring in more cancer drugs and high-end medical devices like stents directly under price regulation, which would have meant capping their prices. However, the proposal faced strong opposition from the department of pharmaceuticals, which raised concerns about already squeezing margins of manufacturers and a threat to introduction of new drugs in the country.&lt;br /&gt;&lt;br /&gt;After the feedback, the health ministry decided to extend CGHS kind of mechanism to cancer medicines and stents for other consumers also, the official said.&lt;br /&gt;&lt;br /&gt;The new proposal is also likely to work in favour of the industry as not only their margins will be protected through bulk supplies but supplying at a negotiated price will also take care of the threat they face from compulsory licences whereby other ompanies are allowed to produce patented drugs in public interest.&lt;br /&gt;&lt;br /&gt;In past few years, several multinationals in India had to face a threat of compulsory licence after generic drug manufacturers claimed that they can make patented oncology and anti-retroviral medicines available at much lower prices. In fact, the first, and so far the only one, compulsory licence granted in India to Natco Pharma was also for a kidney cancer drug Nexavar, originally from Bayer.&lt;br /&gt;&lt;br /&gt;The second application by BDR Pharma seeking CL was also for Bristol-Myers Squibb&#039;s cancer drug Dasatinib. Though it was rejected by the Patent Office, a fresh application was subsequently submitted to the Centre under Section 92 of the Patents Act, which allows such licences to be issued under cases of national emergency. A decision is yet to be taken on the application.&lt;br /&gt;&lt;br /&gt;The latest health ministry&#039;s proposal is likely to get a final shape by end of this year.&lt;br /&gt;&lt;br /&gt;Currently, the government regulates a total of 348 medicine formulations, prices of which are fixed by the National Pharmaceutical Pricing Authority. Companies are free to price all other medicines but with an annual increase of only up to 10%. In case of stents, there is no price control. The government negotiates prices only for those supplied under CGHS.&lt;br /&gt;&lt;br /&gt;&lt;/div&gt;&#039;,
	&#039;lang&#039; =&gt; &#039;English&#039;,
	&#039;SITE_URL&#039; =&gt; &#039;https://im4change.in/&#039;,
	&#039;site_title&#039; =&gt; &#039;im4change&#039;,
	&#039;adminprix&#039; =&gt; &#039;admin&#039;
]
$article_current = object(App\Model\Entity\Article) {

	&#039;id&#039; =&gt; (int) 29209,
	&#039;title&#039; =&gt; &#039;Soon, cancer medicines, stents to be cheaper -Sushmi Dey&#039;,
	&#039;subheading&#039; =&gt; &#039;&#039;,
	&#039;description&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;
-The Times of India&lt;br /&gt;
&lt;br /&gt;
&lt;em&gt;NEW DELHI: &lt;/em&gt;Cancer medicines and stents may soon be available at a substantially lower price. The health ministry is working on a model to procure such drugs in bulk at a negotiated price and supply them to hospitals and consumers through its own retail system like &#039;Jan Aushadhi&#039; stores. .&lt;br /&gt;
&lt;br /&gt;
The idea is to bring down prices of expensive cancer drugs and stents while not putting pressure on margins of companies, a health ministry official told TOI. The government is in talks with pharmaceutical companies to implement the scheme.&lt;br /&gt;
&lt;br /&gt;
Currently, prices of only 51 cancer medicines are capped or regulated by the government. However, several oncologists, public health experts and even institutes like Tata Memorial Cancer Hospital have advocated bringing in more cancer drugs under price control as these medicines are extremely expensive and often out of reach of majority of patients.&lt;br /&gt;
&lt;br /&gt;
Following this, the health ministry had planned to bring in more cancer drugs and high-end medical devices like stents directly under price regulation, which would have meant capping their prices. However, the proposal faced strong opposition from the department of pharmaceuticals, which raised concerns about already squeezing margins of manufacturers and a threat to introduction of new drugs in the country.&lt;br /&gt;
&lt;br /&gt;
After the feedback, the health ministry decided to extend CGHS kind of mechanism to cancer medicines and stents for other consumers also, the official said.&lt;br /&gt;
&lt;br /&gt;
The new proposal is also likely to work in favour of the industry as not only their margins will be protected through bulk supplies but supplying at a negotiated price will also take care of the threat they face from compulsory licences whereby other ompanies are allowed to produce patented drugs in public interest.&lt;br /&gt;
&lt;br /&gt;
In past few years, several multinationals in India had to face a threat of compulsory licence after generic drug manufacturers claimed that they can make patented oncology and anti-retroviral medicines available at much lower prices. In fact, the first, and so far the only one, compulsory licence granted in India to Natco Pharma was also for a kidney cancer drug Nexavar, originally from Bayer.&lt;br /&gt;
&lt;br /&gt;
The second application by BDR Pharma seeking CL was also for Bristol-Myers Squibb&#039;s cancer drug Dasatinib. Though it was rejected by the Patent Office, a fresh application was subsequently submitted to the Centre under Section 92 of the Patents Act, which allows such licences to be issued under cases of national emergency. A decision is yet to be taken on the application.&lt;br /&gt;
&lt;br /&gt;
The latest health ministry&#039;s proposal is likely to get a final shape by end of this year.&lt;br /&gt;
&lt;br /&gt;
Currently, the government regulates a total of 348 medicine formulations, prices of which are fixed by the National Pharmaceutical Pricing Authority. Companies are free to price all other medicines but with an annual increase of only up to 10%. In case of stents, there is no price control. The government negotiates prices only for those supplied under CGHS.&lt;br /&gt;
&lt;br /&gt;
&lt;/div&gt;&#039;,
	&#039;credit_writer&#039; =&gt; &#039;The Times of India, 19 September, 2015, http://timesofindia.indiatimes.com/india/Soon-cancer-medicines-stents-to-be-cheaper/articleshow/49019942.cms&#039;,
	&#039;article_img&#039; =&gt; &#039;&#039;,
	&#039;article_img_thumb&#039; =&gt; &#039;&#039;,
	&#039;status&#039; =&gt; (int) 1,
	&#039;show_on_home&#039; =&gt; (int) 1,
	&#039;lang&#039; =&gt; &#039;EN&#039;,
	&#039;category_id&#039; =&gt; (int) 16,
	&#039;tag_keyword&#039; =&gt; &#039;&#039;,
	&#039;seo_url&#039; =&gt; &#039;soon-cancer-medicines-stents-to-be-cheaper-sushmi-dey-4677264&#039;,
	&#039;meta_title&#039; =&gt; null,
	&#039;meta_keywords&#039; =&gt; null,
	&#039;meta_description&#039; =&gt; null,
	&#039;noindex&#039; =&gt; (int) 0,
	&#039;publish_date&#039; =&gt; object(Cake\I18n\FrozenDate) {},
	&#039;most_visit_section_id&#039; =&gt; null,
	&#039;article_big_img&#039; =&gt; null,
	&#039;liveid&#039; =&gt; (int) 4677264,
	&#039;created&#039; =&gt; object(Cake\I18n\FrozenTime) {},
	&#039;modified&#039; =&gt; object(Cake\I18n\FrozenTime) {},
	&#039;edate&#039; =&gt; &#039;&#039;,
	&#039;tags&#039; =&gt; [
		(int) 0 =&gt; object(Cake\ORM\Entity) {},
		(int) 1 =&gt; object(Cake\ORM\Entity) {},
		(int) 2 =&gt; object(Cake\ORM\Entity) {},
		(int) 3 =&gt; object(Cake\ORM\Entity) {},
		(int) 4 =&gt; object(Cake\ORM\Entity) {},
		(int) 5 =&gt; object(Cake\ORM\Entity) {},
		(int) 6 =&gt; object(Cake\ORM\Entity) {}
	],
	&#039;category&#039; =&gt; object(App\Model\Entity\Category) {},
	&#039;[new]&#039; =&gt; false,
	&#039;[accessible]&#039; =&gt; [
		&#039;*&#039; =&gt; true,
		&#039;id&#039; =&gt; false
	],
	&#039;[dirty]&#039; =&gt; [],
	&#039;[original]&#039; =&gt; [],
	&#039;[virtual]&#039; =&gt; [],
	&#039;[hasErrors]&#039; =&gt; false,
	&#039;[errors]&#039; =&gt; [],
	&#039;[invalid]&#039; =&gt; [],
	&#039;[repository]&#039; =&gt; &#039;Articles&#039;

}
$articleid = (int) 29209
$metaTitle = &#039;LATEST NEWS UPDATES | Soon, cancer medicines, stents to be cheaper -Sushmi Dey&#039;
$metaKeywords = &#039;generic medicine,Compulsory license,Access to Health,Access to Healthcare,Access to Medicines,Cancer,medicines&#039;
$metaDesc = &#039;
-The Times of India

NEW DELHI: Cancer medicines and stents may soon be available at a substantially lower price. The health ministry is working on a model to procure such drugs in bulk at a negotiated price and supply them to...&#039;
$disp = &#039;&lt;div align=&quot;justify&quot;&gt;-The Times of India&lt;br /&gt;&lt;br /&gt;&lt;em&gt;NEW DELHI: &lt;/em&gt;Cancer medicines and stents may soon be available at a substantially lower price. The health ministry is working on a model to procure such drugs in bulk at a negotiated price and supply them to hospitals and consumers through its own retail system like &#039;Jan Aushadhi&#039; stores. .&lt;br /&gt;&lt;br /&gt;The idea is to bring down prices of expensive cancer drugs and stents while not putting pressure on margins of companies, a health ministry official told TOI. The government is in talks with pharmaceutical companies to implement the scheme.&lt;br /&gt;&lt;br /&gt;Currently, prices of only 51 cancer medicines are capped or regulated by the government. However, several oncologists, public health experts and even institutes like Tata Memorial Cancer Hospital have advocated bringing in more cancer drugs under price control as these medicines are extremely expensive and often out of reach of majority of patients.&lt;br /&gt;&lt;br /&gt;Following this, the health ministry had planned to bring in more cancer drugs and high-end medical devices like stents directly under price regulation, which would have meant capping their prices. However, the proposal faced strong opposition from the department of pharmaceuticals, which raised concerns about already squeezing margins of manufacturers and a threat to introduction of new drugs in the country.&lt;br /&gt;&lt;br /&gt;After the feedback, the health ministry decided to extend CGHS kind of mechanism to cancer medicines and stents for other consumers also, the official said.&lt;br /&gt;&lt;br /&gt;The new proposal is also likely to work in favour of the industry as not only their margins will be protected through bulk supplies but supplying at a negotiated price will also take care of the threat they face from compulsory licences whereby other ompanies are allowed to produce patented drugs in public interest.&lt;br /&gt;&lt;br /&gt;In past few years, several multinationals in India had to face a threat of compulsory licence after generic drug manufacturers claimed that they can make patented oncology and anti-retroviral medicines available at much lower prices. In fact, the first, and so far the only one, compulsory licence granted in India to Natco Pharma was also for a kidney cancer drug Nexavar, originally from Bayer.&lt;br /&gt;&lt;br /&gt;The second application by BDR Pharma seeking CL was also for Bristol-Myers Squibb&#039;s cancer drug Dasatinib. Though it was rejected by the Patent Office, a fresh application was subsequently submitted to the Centre under Section 92 of the Patents Act, which allows such licences to be issued under cases of national emergency. A decision is yet to be taken on the application.&lt;br /&gt;&lt;br /&gt;The latest health ministry&#039;s proposal is likely to get a final shape by end of this year.&lt;br /&gt;&lt;br /&gt;Currently, the government regulates a total of 348 medicine formulations, prices of which are fixed by the National Pharmaceutical Pricing Authority. Companies are free to price all other medicines but with an annual increase of only up to 10%. In case of stents, there is no price control. The government negotiates prices only for those supplied under CGHS.&lt;br /&gt;&lt;br /&gt;&lt;/div&gt;&#039;
$lang = &#039;English&#039;
$SITE_URL = &#039;https://im4change.in/&#039;
$site_title = &#039;im4change&#039;
$adminprix = &#039;admin&#039;</pre><pre class="stack-trace">include - APP/Template/Layout/printlayout.ctp, line 8
Cake\View\View::_evaluate() - CORE/src/View/View.php, line 1413
Cake\View\View::_render() - CORE/src/View/View.php, line 1374
Cake\View\View::renderLayout() - CORE/src/View/View.php, line 927
Cake\View\View::render() - CORE/src/View/View.php, line 885
Cake\Controller\Controller::render() - CORE/src/Controller/Controller.php, line 791
Cake\Http\ActionDispatcher::_invoke() - CORE/src/Http/ActionDispatcher.php, line 126
Cake\Http\ActionDispatcher::dispatch() - CORE/src/Http/ActionDispatcher.php, line 94
Cake\Http\BaseApplication::__invoke() - CORE/src/Http/BaseApplication.php, line 235
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\RoutingMiddleware::__invoke() - CORE/src/Routing/Middleware/RoutingMiddleware.php, line 162
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\AssetMiddleware::__invoke() - CORE/src/Routing/Middleware/AssetMiddleware.php, line 88
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Error\Middleware\ErrorHandlerMiddleware::__invoke() - CORE/src/Error/Middleware/ErrorHandlerMiddleware.php, line 96
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Http\Runner::run() - CORE/src/Http/Runner.php, line 51</pre></div></pre>latest-news-updates/soon-cancer-medicines-stents-to-be-cheaper-sushmi-dey-4677264.html"/>
    <meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>
    <link href="https://im4change.in/css/control.css" rel="stylesheet" type="text/css"
          media="all"/>
    <title>LATEST NEWS UPDATES | Soon, cancer medicines, stents to be cheaper -Sushmi Dey | Im4change.org</title>
    <meta name="description" content="
-The Times of India

NEW DELHI: Cancer medicines and stents may soon be available at a substantially lower price. The health ministry is working on a model to procure such drugs in bulk at a negotiated price and supply them to..."/>
    <script src="https://im4change.in/js/jquery-1.10.2.js"></script>
    <script type="text/javascript" src="https://im4change.in/js/jquery-migrate.min.js"></script>
    <script language="javascript" type="text/javascript">

        $(document).ready(function () {
            var img = $("img")[0]; // Get my img elem
            var pic_real_width, pic_real_height;
            $("<img/>") // Make in memory copy of image to avoid css issues
                .attr("src", $(img).attr("src"))
                .load(function () {
                    pic_real_width = this.width;   // Note: $(this).width() will not
                    pic_real_height = this.height; // work for in memory images.
                });
        });
    </script>
    <style type="text/css">
        @media screen {
            div.divFooter {
                display: block;
            }
        }

        @media print {
            .printbutton {
                display: none !important;
            }
        }
    </style>
</head>
<body>
<table cellpadding="0" cellspacing="0" border="0" width="98%" align="center">
    <tr>
        <td class="top_bg">
            <div class="divFooter">
                <img src="https://im4change.in/images/logo1.jpg" height="59" border="0"
                     alt="Resource centre on India's rural distress" style="padding-top:14px;"/>
            </div>

        </td>
    </tr>
    <tr>
        <td id="topspace">&nbsp;</td>
    </tr>

    <tr id="topspace">
        <td>&nbsp;</td>
    </tr>
    <tr>
        <td height="50" style="border-bottom:1px solid #000; padding-top:10px;" class="printbutton">
            <form><input type="button" value=" Print this page "
                         onclick="window.print();return false;"/></form>
        </td>
    </tr>

    <tr>
        <td width="100%">
            <h1 class="news_headlines" style="font-style:normal">
                <strong>Soon, cancer medicines, stents to be cheaper -Sushmi Dey</strong></h1>
        </td>
    </tr>
    <tr>
        <td width="100%" style="font-family:Arial, 'Segoe Script', 'Segoe UI', sans-serif, serif"><font size="3">
                <div align="justify">-The Times of India<br /><br /><em>NEW DELHI: </em>Cancer medicines and stents may soon be available at a substantially lower price. The health ministry is working on a model to procure such drugs in bulk at a negotiated price and supply them to hospitals and consumers through its own retail system like 'Jan Aushadhi' stores. .<br /><br />The idea is to bring down prices of expensive cancer drugs and stents while not putting pressure on margins of companies, a health ministry official told TOI. The government is in talks with pharmaceutical companies to implement the scheme.<br /><br />Currently, prices of only 51 cancer medicines are capped or regulated by the government. However, several oncologists, public health experts and even institutes like Tata Memorial Cancer Hospital have advocated bringing in more cancer drugs under price control as these medicines are extremely expensive and often out of reach of majority of patients.<br /><br />Following this, the health ministry had planned to bring in more cancer drugs and high-end medical devices like stents directly under price regulation, which would have meant capping their prices. However, the proposal faced strong opposition from the department of pharmaceuticals, which raised concerns about already squeezing margins of manufacturers and a threat to introduction of new drugs in the country.<br /><br />After the feedback, the health ministry decided to extend CGHS kind of mechanism to cancer medicines and stents for other consumers also, the official said.<br /><br />The new proposal is also likely to work in favour of the industry as not only their margins will be protected through bulk supplies but supplying at a negotiated price will also take care of the threat they face from compulsory licences whereby other ompanies are allowed to produce patented drugs in public interest.<br /><br />In past few years, several multinationals in India had to face a threat of compulsory licence after generic drug manufacturers claimed that they can make patented oncology and anti-retroviral medicines available at much lower prices. In fact, the first, and so far the only one, compulsory licence granted in India to Natco Pharma was also for a kidney cancer drug Nexavar, originally from Bayer.<br /><br />The second application by BDR Pharma seeking CL was also for Bristol-Myers Squibb's cancer drug Dasatinib. Though it was rejected by the Patent Office, a fresh application was subsequently submitted to the Centre under Section 92 of the Patents Act, which allows such licences to be issued under cases of national emergency. A decision is yet to be taken on the application.<br /><br />The latest health ministry's proposal is likely to get a final shape by end of this year.<br /><br />Currently, the government regulates a total of 348 medicine formulations, prices of which are fixed by the National Pharmaceutical Pricing Authority. Companies are free to price all other medicines but with an annual increase of only up to 10%. In case of stents, there is no price control. The government negotiates prices only for those supplied under CGHS.<br /><br /></div>               </font>
        </td>
    </tr>
    <tr>
        <td>&nbsp;</td>
    </tr>

    <tr>
        <td height="50" style="border-top:1px solid #000; border-bottom:1px solid #000;padding-top:10px;">
            <form><input type="button" value=" Print this page "
                         onclick="window.print();return false;"/></form>
        </td>
    </tr>
</table></body>
</html>'

}
$maxBufferLength = (int) 8192
$file = '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Debugger.php'
$line = (int) 853
$message = 'Unable to emit headers. Headers sent in file=/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Debugger.php line=853'
Cake\Http\ResponseEmitter::emit() - CORE/src/Http/ResponseEmitter.php, line 48
Cake\Http\Server::emit() - CORE/src/Http/Server.php, line 141
[main] - ROOT/webroot/index.php, line 39

Warning (2): Cannot modify header information - headers already sent by (output started at /home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Debugger.php:853) [CORE/src/Http/ResponseEmitter.php, line 148]
Code Context
            $response->getStatusCode(),

            ($reasonPhrase ? ' ' . $reasonPhrase : '')

        ));
$response = object(Cake\Http\Response) {

	'status' => (int) 200,
	'contentType' => 'text/html',
	'headers' => [
		'Content-Type' => [
			[maximum depth reached]
		]
	],
	'file' => null,
	'fileRange' => [],
	'cookies' => object(Cake\Http\Cookie\CookieCollection) {},
	'cacheDirectives' => [],
	'body' => '<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN"
        "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml">
<head>
    <link rel="canonical" href="https://im4change.in/<pre class="cake-error"><a href="javascript:void(0);" onclick="document.getElementById('cakeErr67fe7e3ca7549-trace').style.display = (document.getElementById('cakeErr67fe7e3ca7549-trace').style.display == 'none' ? '' : 'none');"><b>Notice</b> (8)</a>: Undefined variable: urlPrefix [<b>APP/Template/Layout/printlayout.ctp</b>, line <b>8</b>]<div id="cakeErr67fe7e3ca7549-trace" class="cake-stack-trace" style="display: none;"><a href="javascript:void(0);" onclick="document.getElementById('cakeErr67fe7e3ca7549-code').style.display = (document.getElementById('cakeErr67fe7e3ca7549-code').style.display == 'none' ? '' : 'none')">Code</a> <a href="javascript:void(0);" onclick="document.getElementById('cakeErr67fe7e3ca7549-context').style.display = (document.getElementById('cakeErr67fe7e3ca7549-context').style.display == 'none' ? '' : 'none')">Context</a><pre id="cakeErr67fe7e3ca7549-code" class="cake-code-dump" style="display: none;"><code><span style="color: #000000"><span style="color: #0000BB"></span><span style="color: #007700">&lt;</span><span style="color: #0000BB">head</span><span style="color: #007700">&gt;
</span></span></code>
<span class="code-highlight"><code><span style="color: #000000">&nbsp;&nbsp;&nbsp;&nbsp;&lt;link&nbsp;rel="canonical"&nbsp;href="<span style="color: #0000BB">&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">Configure</span><span style="color: #007700">::</span><span style="color: #0000BB">read</span><span style="color: #007700">(</span><span style="color: #DD0000">'SITE_URL'</span><span style="color: #007700">);&nbsp;</span><span style="color: #0000BB">?&gt;&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$urlPrefix</span><span style="color: #007700">;</span><span style="color: #0000BB">?&gt;&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$article_current</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">category</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">slug</span><span style="color: #007700">;&nbsp;</span><span style="color: #0000BB">?&gt;</span>/<span style="color: #0000BB">&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$article_current</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">seo_url</span><span style="color: #007700">;&nbsp;</span><span style="color: #0000BB">?&gt;</span>.html"/&gt;
</span></code></span>
<code><span style="color: #000000"><span style="color: #0000BB">&nbsp;&nbsp;&nbsp;&nbsp;</span><span style="color: #007700">&lt;</span><span style="color: #0000BB">meta&nbsp;http</span><span style="color: #007700">-</span><span style="color: #0000BB">equiv</span><span style="color: #007700">=</span><span style="color: #DD0000">"Content-Type"&nbsp;</span><span style="color: #0000BB">content</span><span style="color: #007700">=</span><span style="color: #DD0000">"text/html;&nbsp;charset=utf-8"</span><span style="color: #007700">/&gt;
</span></span></code></pre><pre id="cakeErr67fe7e3ca7549-context" class="cake-context" style="display: none;">$viewFile = &#039;/home/brlfuser/public_html/src/Template/Layout/printlayout.ctp&#039;
$dataForView = [
	&#039;article_current&#039; =&gt; object(App\Model\Entity\Article) {

		&#039;id&#039; =&gt; (int) 29209,
		&#039;title&#039; =&gt; &#039;Soon, cancer medicines, stents to be cheaper -Sushmi Dey&#039;,
		&#039;subheading&#039; =&gt; &#039;&#039;,
		&#039;description&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;
-The Times of India&lt;br /&gt;
&lt;br /&gt;
&lt;em&gt;NEW DELHI: &lt;/em&gt;Cancer medicines and stents may soon be available at a substantially lower price. The health ministry is working on a model to procure such drugs in bulk at a negotiated price and supply them to hospitals and consumers through its own retail system like &#039;Jan Aushadhi&#039; stores. .&lt;br /&gt;
&lt;br /&gt;
The idea is to bring down prices of expensive cancer drugs and stents while not putting pressure on margins of companies, a health ministry official told TOI. The government is in talks with pharmaceutical companies to implement the scheme.&lt;br /&gt;
&lt;br /&gt;
Currently, prices of only 51 cancer medicines are capped or regulated by the government. However, several oncologists, public health experts and even institutes like Tata Memorial Cancer Hospital have advocated bringing in more cancer drugs under price control as these medicines are extremely expensive and often out of reach of majority of patients.&lt;br /&gt;
&lt;br /&gt;
Following this, the health ministry had planned to bring in more cancer drugs and high-end medical devices like stents directly under price regulation, which would have meant capping their prices. However, the proposal faced strong opposition from the department of pharmaceuticals, which raised concerns about already squeezing margins of manufacturers and a threat to introduction of new drugs in the country.&lt;br /&gt;
&lt;br /&gt;
After the feedback, the health ministry decided to extend CGHS kind of mechanism to cancer medicines and stents for other consumers also, the official said.&lt;br /&gt;
&lt;br /&gt;
The new proposal is also likely to work in favour of the industry as not only their margins will be protected through bulk supplies but supplying at a negotiated price will also take care of the threat they face from compulsory licences whereby other ompanies are allowed to produce patented drugs in public interest.&lt;br /&gt;
&lt;br /&gt;
In past few years, several multinationals in India had to face a threat of compulsory licence after generic drug manufacturers claimed that they can make patented oncology and anti-retroviral medicines available at much lower prices. In fact, the first, and so far the only one, compulsory licence granted in India to Natco Pharma was also for a kidney cancer drug Nexavar, originally from Bayer.&lt;br /&gt;
&lt;br /&gt;
The second application by BDR Pharma seeking CL was also for Bristol-Myers Squibb&#039;s cancer drug Dasatinib. Though it was rejected by the Patent Office, a fresh application was subsequently submitted to the Centre under Section 92 of the Patents Act, which allows such licences to be issued under cases of national emergency. A decision is yet to be taken on the application.&lt;br /&gt;
&lt;br /&gt;
The latest health ministry&#039;s proposal is likely to get a final shape by end of this year.&lt;br /&gt;
&lt;br /&gt;
Currently, the government regulates a total of 348 medicine formulations, prices of which are fixed by the National Pharmaceutical Pricing Authority. Companies are free to price all other medicines but with an annual increase of only up to 10%. In case of stents, there is no price control. The government negotiates prices only for those supplied under CGHS.&lt;br /&gt;
&lt;br /&gt;
&lt;/div&gt;&#039;,
		&#039;credit_writer&#039; =&gt; &#039;The Times of India, 19 September, 2015, http://timesofindia.indiatimes.com/india/Soon-cancer-medicines-stents-to-be-cheaper/articleshow/49019942.cms&#039;,
		&#039;article_img&#039; =&gt; &#039;&#039;,
		&#039;article_img_thumb&#039; =&gt; &#039;&#039;,
		&#039;status&#039; =&gt; (int) 1,
		&#039;show_on_home&#039; =&gt; (int) 1,
		&#039;lang&#039; =&gt; &#039;EN&#039;,
		&#039;category_id&#039; =&gt; (int) 16,
		&#039;tag_keyword&#039; =&gt; &#039;&#039;,
		&#039;seo_url&#039; =&gt; &#039;soon-cancer-medicines-stents-to-be-cheaper-sushmi-dey-4677264&#039;,
		&#039;meta_title&#039; =&gt; null,
		&#039;meta_keywords&#039; =&gt; null,
		&#039;meta_description&#039; =&gt; null,
		&#039;noindex&#039; =&gt; (int) 0,
		&#039;publish_date&#039; =&gt; object(Cake\I18n\FrozenDate) {},
		&#039;most_visit_section_id&#039; =&gt; null,
		&#039;article_big_img&#039; =&gt; null,
		&#039;liveid&#039; =&gt; (int) 4677264,
		&#039;created&#039; =&gt; object(Cake\I18n\FrozenTime) {},
		&#039;modified&#039; =&gt; object(Cake\I18n\FrozenTime) {},
		&#039;edate&#039; =&gt; &#039;&#039;,
		&#039;tags&#039; =&gt; [
			[maximum depth reached]
		],
		&#039;category&#039; =&gt; object(App\Model\Entity\Category) {},
		&#039;[new]&#039; =&gt; false,
		&#039;[accessible]&#039; =&gt; [
			[maximum depth reached]
		],
		&#039;[dirty]&#039; =&gt; [[maximum depth reached]],
		&#039;[original]&#039; =&gt; [[maximum depth reached]],
		&#039;[virtual]&#039; =&gt; [[maximum depth reached]],
		&#039;[hasErrors]&#039; =&gt; false,
		&#039;[errors]&#039; =&gt; [[maximum depth reached]],
		&#039;[invalid]&#039; =&gt; [[maximum depth reached]],
		&#039;[repository]&#039; =&gt; &#039;Articles&#039;
	
	},
	&#039;articleid&#039; =&gt; (int) 29209,
	&#039;metaTitle&#039; =&gt; &#039;LATEST NEWS UPDATES | Soon, cancer medicines, stents to be cheaper -Sushmi Dey&#039;,
	&#039;metaKeywords&#039; =&gt; &#039;generic medicine,Compulsory license,Access to Health,Access to Healthcare,Access to Medicines,Cancer,medicines&#039;,
	&#039;metaDesc&#039; =&gt; &#039;
-The Times of India

NEW DELHI: Cancer medicines and stents may soon be available at a substantially lower price. The health ministry is working on a model to procure such drugs in bulk at a negotiated price and supply them to...&#039;,
	&#039;disp&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;-The Times of India&lt;br /&gt;&lt;br /&gt;&lt;em&gt;NEW DELHI: &lt;/em&gt;Cancer medicines and stents may soon be available at a substantially lower price. The health ministry is working on a model to procure such drugs in bulk at a negotiated price and supply them to hospitals and consumers through its own retail system like &#039;Jan Aushadhi&#039; stores. .&lt;br /&gt;&lt;br /&gt;The idea is to bring down prices of expensive cancer drugs and stents while not putting pressure on margins of companies, a health ministry official told TOI. The government is in talks with pharmaceutical companies to implement the scheme.&lt;br /&gt;&lt;br /&gt;Currently, prices of only 51 cancer medicines are capped or regulated by the government. However, several oncologists, public health experts and even institutes like Tata Memorial Cancer Hospital have advocated bringing in more cancer drugs under price control as these medicines are extremely expensive and often out of reach of majority of patients.&lt;br /&gt;&lt;br /&gt;Following this, the health ministry had planned to bring in more cancer drugs and high-end medical devices like stents directly under price regulation, which would have meant capping their prices. However, the proposal faced strong opposition from the department of pharmaceuticals, which raised concerns about already squeezing margins of manufacturers and a threat to introduction of new drugs in the country.&lt;br /&gt;&lt;br /&gt;After the feedback, the health ministry decided to extend CGHS kind of mechanism to cancer medicines and stents for other consumers also, the official said.&lt;br /&gt;&lt;br /&gt;The new proposal is also likely to work in favour of the industry as not only their margins will be protected through bulk supplies but supplying at a negotiated price will also take care of the threat they face from compulsory licences whereby other ompanies are allowed to produce patented drugs in public interest.&lt;br /&gt;&lt;br /&gt;In past few years, several multinationals in India had to face a threat of compulsory licence after generic drug manufacturers claimed that they can make patented oncology and anti-retroviral medicines available at much lower prices. In fact, the first, and so far the only one, compulsory licence granted in India to Natco Pharma was also for a kidney cancer drug Nexavar, originally from Bayer.&lt;br /&gt;&lt;br /&gt;The second application by BDR Pharma seeking CL was also for Bristol-Myers Squibb&#039;s cancer drug Dasatinib. Though it was rejected by the Patent Office, a fresh application was subsequently submitted to the Centre under Section 92 of the Patents Act, which allows such licences to be issued under cases of national emergency. A decision is yet to be taken on the application.&lt;br /&gt;&lt;br /&gt;The latest health ministry&#039;s proposal is likely to get a final shape by end of this year.&lt;br /&gt;&lt;br /&gt;Currently, the government regulates a total of 348 medicine formulations, prices of which are fixed by the National Pharmaceutical Pricing Authority. Companies are free to price all other medicines but with an annual increase of only up to 10%. In case of stents, there is no price control. The government negotiates prices only for those supplied under CGHS.&lt;br /&gt;&lt;br /&gt;&lt;/div&gt;&#039;,
	&#039;lang&#039; =&gt; &#039;English&#039;,
	&#039;SITE_URL&#039; =&gt; &#039;https://im4change.in/&#039;,
	&#039;site_title&#039; =&gt; &#039;im4change&#039;,
	&#039;adminprix&#039; =&gt; &#039;admin&#039;
]
$article_current = object(App\Model\Entity\Article) {

	&#039;id&#039; =&gt; (int) 29209,
	&#039;title&#039; =&gt; &#039;Soon, cancer medicines, stents to be cheaper -Sushmi Dey&#039;,
	&#039;subheading&#039; =&gt; &#039;&#039;,
	&#039;description&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;
-The Times of India&lt;br /&gt;
&lt;br /&gt;
&lt;em&gt;NEW DELHI: &lt;/em&gt;Cancer medicines and stents may soon be available at a substantially lower price. The health ministry is working on a model to procure such drugs in bulk at a negotiated price and supply them to hospitals and consumers through its own retail system like &#039;Jan Aushadhi&#039; stores. .&lt;br /&gt;
&lt;br /&gt;
The idea is to bring down prices of expensive cancer drugs and stents while not putting pressure on margins of companies, a health ministry official told TOI. The government is in talks with pharmaceutical companies to implement the scheme.&lt;br /&gt;
&lt;br /&gt;
Currently, prices of only 51 cancer medicines are capped or regulated by the government. However, several oncologists, public health experts and even institutes like Tata Memorial Cancer Hospital have advocated bringing in more cancer drugs under price control as these medicines are extremely expensive and often out of reach of majority of patients.&lt;br /&gt;
&lt;br /&gt;
Following this, the health ministry had planned to bring in more cancer drugs and high-end medical devices like stents directly under price regulation, which would have meant capping their prices. However, the proposal faced strong opposition from the department of pharmaceuticals, which raised concerns about already squeezing margins of manufacturers and a threat to introduction of new drugs in the country.&lt;br /&gt;
&lt;br /&gt;
After the feedback, the health ministry decided to extend CGHS kind of mechanism to cancer medicines and stents for other consumers also, the official said.&lt;br /&gt;
&lt;br /&gt;
The new proposal is also likely to work in favour of the industry as not only their margins will be protected through bulk supplies but supplying at a negotiated price will also take care of the threat they face from compulsory licences whereby other ompanies are allowed to produce patented drugs in public interest.&lt;br /&gt;
&lt;br /&gt;
In past few years, several multinationals in India had to face a threat of compulsory licence after generic drug manufacturers claimed that they can make patented oncology and anti-retroviral medicines available at much lower prices. In fact, the first, and so far the only one, compulsory licence granted in India to Natco Pharma was also for a kidney cancer drug Nexavar, originally from Bayer.&lt;br /&gt;
&lt;br /&gt;
The second application by BDR Pharma seeking CL was also for Bristol-Myers Squibb&#039;s cancer drug Dasatinib. Though it was rejected by the Patent Office, a fresh application was subsequently submitted to the Centre under Section 92 of the Patents Act, which allows such licences to be issued under cases of national emergency. A decision is yet to be taken on the application.&lt;br /&gt;
&lt;br /&gt;
The latest health ministry&#039;s proposal is likely to get a final shape by end of this year.&lt;br /&gt;
&lt;br /&gt;
Currently, the government regulates a total of 348 medicine formulations, prices of which are fixed by the National Pharmaceutical Pricing Authority. Companies are free to price all other medicines but with an annual increase of only up to 10%. In case of stents, there is no price control. The government negotiates prices only for those supplied under CGHS.&lt;br /&gt;
&lt;br /&gt;
&lt;/div&gt;&#039;,
	&#039;credit_writer&#039; =&gt; &#039;The Times of India, 19 September, 2015, http://timesofindia.indiatimes.com/india/Soon-cancer-medicines-stents-to-be-cheaper/articleshow/49019942.cms&#039;,
	&#039;article_img&#039; =&gt; &#039;&#039;,
	&#039;article_img_thumb&#039; =&gt; &#039;&#039;,
	&#039;status&#039; =&gt; (int) 1,
	&#039;show_on_home&#039; =&gt; (int) 1,
	&#039;lang&#039; =&gt; &#039;EN&#039;,
	&#039;category_id&#039; =&gt; (int) 16,
	&#039;tag_keyword&#039; =&gt; &#039;&#039;,
	&#039;seo_url&#039; =&gt; &#039;soon-cancer-medicines-stents-to-be-cheaper-sushmi-dey-4677264&#039;,
	&#039;meta_title&#039; =&gt; null,
	&#039;meta_keywords&#039; =&gt; null,
	&#039;meta_description&#039; =&gt; null,
	&#039;noindex&#039; =&gt; (int) 0,
	&#039;publish_date&#039; =&gt; object(Cake\I18n\FrozenDate) {},
	&#039;most_visit_section_id&#039; =&gt; null,
	&#039;article_big_img&#039; =&gt; null,
	&#039;liveid&#039; =&gt; (int) 4677264,
	&#039;created&#039; =&gt; object(Cake\I18n\FrozenTime) {},
	&#039;modified&#039; =&gt; object(Cake\I18n\FrozenTime) {},
	&#039;edate&#039; =&gt; &#039;&#039;,
	&#039;tags&#039; =&gt; [
		(int) 0 =&gt; object(Cake\ORM\Entity) {},
		(int) 1 =&gt; object(Cake\ORM\Entity) {},
		(int) 2 =&gt; object(Cake\ORM\Entity) {},
		(int) 3 =&gt; object(Cake\ORM\Entity) {},
		(int) 4 =&gt; object(Cake\ORM\Entity) {},
		(int) 5 =&gt; object(Cake\ORM\Entity) {},
		(int) 6 =&gt; object(Cake\ORM\Entity) {}
	],
	&#039;category&#039; =&gt; object(App\Model\Entity\Category) {},
	&#039;[new]&#039; =&gt; false,
	&#039;[accessible]&#039; =&gt; [
		&#039;*&#039; =&gt; true,
		&#039;id&#039; =&gt; false
	],
	&#039;[dirty]&#039; =&gt; [],
	&#039;[original]&#039; =&gt; [],
	&#039;[virtual]&#039; =&gt; [],
	&#039;[hasErrors]&#039; =&gt; false,
	&#039;[errors]&#039; =&gt; [],
	&#039;[invalid]&#039; =&gt; [],
	&#039;[repository]&#039; =&gt; &#039;Articles&#039;

}
$articleid = (int) 29209
$metaTitle = &#039;LATEST NEWS UPDATES | Soon, cancer medicines, stents to be cheaper -Sushmi Dey&#039;
$metaKeywords = &#039;generic medicine,Compulsory license,Access to Health,Access to Healthcare,Access to Medicines,Cancer,medicines&#039;
$metaDesc = &#039;
-The Times of India

NEW DELHI: Cancer medicines and stents may soon be available at a substantially lower price. The health ministry is working on a model to procure such drugs in bulk at a negotiated price and supply them to...&#039;
$disp = &#039;&lt;div align=&quot;justify&quot;&gt;-The Times of India&lt;br /&gt;&lt;br /&gt;&lt;em&gt;NEW DELHI: &lt;/em&gt;Cancer medicines and stents may soon be available at a substantially lower price. The health ministry is working on a model to procure such drugs in bulk at a negotiated price and supply them to hospitals and consumers through its own retail system like &#039;Jan Aushadhi&#039; stores. .&lt;br /&gt;&lt;br /&gt;The idea is to bring down prices of expensive cancer drugs and stents while not putting pressure on margins of companies, a health ministry official told TOI. The government is in talks with pharmaceutical companies to implement the scheme.&lt;br /&gt;&lt;br /&gt;Currently, prices of only 51 cancer medicines are capped or regulated by the government. However, several oncologists, public health experts and even institutes like Tata Memorial Cancer Hospital have advocated bringing in more cancer drugs under price control as these medicines are extremely expensive and often out of reach of majority of patients.&lt;br /&gt;&lt;br /&gt;Following this, the health ministry had planned to bring in more cancer drugs and high-end medical devices like stents directly under price regulation, which would have meant capping their prices. However, the proposal faced strong opposition from the department of pharmaceuticals, which raised concerns about already squeezing margins of manufacturers and a threat to introduction of new drugs in the country.&lt;br /&gt;&lt;br /&gt;After the feedback, the health ministry decided to extend CGHS kind of mechanism to cancer medicines and stents for other consumers also, the official said.&lt;br /&gt;&lt;br /&gt;The new proposal is also likely to work in favour of the industry as not only their margins will be protected through bulk supplies but supplying at a negotiated price will also take care of the threat they face from compulsory licences whereby other ompanies are allowed to produce patented drugs in public interest.&lt;br /&gt;&lt;br /&gt;In past few years, several multinationals in India had to face a threat of compulsory licence after generic drug manufacturers claimed that they can make patented oncology and anti-retroviral medicines available at much lower prices. In fact, the first, and so far the only one, compulsory licence granted in India to Natco Pharma was also for a kidney cancer drug Nexavar, originally from Bayer.&lt;br /&gt;&lt;br /&gt;The second application by BDR Pharma seeking CL was also for Bristol-Myers Squibb&#039;s cancer drug Dasatinib. Though it was rejected by the Patent Office, a fresh application was subsequently submitted to the Centre under Section 92 of the Patents Act, which allows such licences to be issued under cases of national emergency. A decision is yet to be taken on the application.&lt;br /&gt;&lt;br /&gt;The latest health ministry&#039;s proposal is likely to get a final shape by end of this year.&lt;br /&gt;&lt;br /&gt;Currently, the government regulates a total of 348 medicine formulations, prices of which are fixed by the National Pharmaceutical Pricing Authority. Companies are free to price all other medicines but with an annual increase of only up to 10%. In case of stents, there is no price control. The government negotiates prices only for those supplied under CGHS.&lt;br /&gt;&lt;br /&gt;&lt;/div&gt;&#039;
$lang = &#039;English&#039;
$SITE_URL = &#039;https://im4change.in/&#039;
$site_title = &#039;im4change&#039;
$adminprix = &#039;admin&#039;</pre><pre class="stack-trace">include - APP/Template/Layout/printlayout.ctp, line 8
Cake\View\View::_evaluate() - CORE/src/View/View.php, line 1413
Cake\View\View::_render() - CORE/src/View/View.php, line 1374
Cake\View\View::renderLayout() - CORE/src/View/View.php, line 927
Cake\View\View::render() - CORE/src/View/View.php, line 885
Cake\Controller\Controller::render() - CORE/src/Controller/Controller.php, line 791
Cake\Http\ActionDispatcher::_invoke() - CORE/src/Http/ActionDispatcher.php, line 126
Cake\Http\ActionDispatcher::dispatch() - CORE/src/Http/ActionDispatcher.php, line 94
Cake\Http\BaseApplication::__invoke() - CORE/src/Http/BaseApplication.php, line 235
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\RoutingMiddleware::__invoke() - CORE/src/Routing/Middleware/RoutingMiddleware.php, line 162
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\AssetMiddleware::__invoke() - CORE/src/Routing/Middleware/AssetMiddleware.php, line 88
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Error\Middleware\ErrorHandlerMiddleware::__invoke() - CORE/src/Error/Middleware/ErrorHandlerMiddleware.php, line 96
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Http\Runner::run() - CORE/src/Http/Runner.php, line 51</pre></div></pre>latest-news-updates/soon-cancer-medicines-stents-to-be-cheaper-sushmi-dey-4677264.html"/>
    <meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>
    <link href="https://im4change.in/css/control.css" rel="stylesheet" type="text/css"
          media="all"/>
    <title>LATEST NEWS UPDATES | Soon, cancer medicines, stents to be cheaper -Sushmi Dey | Im4change.org</title>
    <meta name="description" content="
-The Times of India

NEW DELHI: Cancer medicines and stents may soon be available at a substantially lower price. The health ministry is working on a model to procure such drugs in bulk at a negotiated price and supply them to..."/>
    <script src="https://im4change.in/js/jquery-1.10.2.js"></script>
    <script type="text/javascript" src="https://im4change.in/js/jquery-migrate.min.js"></script>
    <script language="javascript" type="text/javascript">

        $(document).ready(function () {
            var img = $("img")[0]; // Get my img elem
            var pic_real_width, pic_real_height;
            $("<img/>") // Make in memory copy of image to avoid css issues
                .attr("src", $(img).attr("src"))
                .load(function () {
                    pic_real_width = this.width;   // Note: $(this).width() will not
                    pic_real_height = this.height; // work for in memory images.
                });
        });
    </script>
    <style type="text/css">
        @media screen {
            div.divFooter {
                display: block;
            }
        }

        @media print {
            .printbutton {
                display: none !important;
            }
        }
    </style>
</head>
<body>
<table cellpadding="0" cellspacing="0" border="0" width="98%" align="center">
    <tr>
        <td class="top_bg">
            <div class="divFooter">
                <img src="https://im4change.in/images/logo1.jpg" height="59" border="0"
                     alt="Resource centre on India's rural distress" style="padding-top:14px;"/>
            </div>

        </td>
    </tr>
    <tr>
        <td id="topspace">&nbsp;</td>
    </tr>

    <tr id="topspace">
        <td>&nbsp;</td>
    </tr>
    <tr>
        <td height="50" style="border-bottom:1px solid #000; padding-top:10px;" class="printbutton">
            <form><input type="button" value=" Print this page "
                         onclick="window.print();return false;"/></form>
        </td>
    </tr>

    <tr>
        <td width="100%">
            <h1 class="news_headlines" style="font-style:normal">
                <strong>Soon, cancer medicines, stents to be cheaper -Sushmi Dey</strong></h1>
        </td>
    </tr>
    <tr>
        <td width="100%" style="font-family:Arial, 'Segoe Script', 'Segoe UI', sans-serif, serif"><font size="3">
                <div align="justify">-The Times of India<br /><br /><em>NEW DELHI: </em>Cancer medicines and stents may soon be available at a substantially lower price. The health ministry is working on a model to procure such drugs in bulk at a negotiated price and supply them to hospitals and consumers through its own retail system like 'Jan Aushadhi' stores. .<br /><br />The idea is to bring down prices of expensive cancer drugs and stents while not putting pressure on margins of companies, a health ministry official told TOI. The government is in talks with pharmaceutical companies to implement the scheme.<br /><br />Currently, prices of only 51 cancer medicines are capped or regulated by the government. However, several oncologists, public health experts and even institutes like Tata Memorial Cancer Hospital have advocated bringing in more cancer drugs under price control as these medicines are extremely expensive and often out of reach of majority of patients.<br /><br />Following this, the health ministry had planned to bring in more cancer drugs and high-end medical devices like stents directly under price regulation, which would have meant capping their prices. However, the proposal faced strong opposition from the department of pharmaceuticals, which raised concerns about already squeezing margins of manufacturers and a threat to introduction of new drugs in the country.<br /><br />After the feedback, the health ministry decided to extend CGHS kind of mechanism to cancer medicines and stents for other consumers also, the official said.<br /><br />The new proposal is also likely to work in favour of the industry as not only their margins will be protected through bulk supplies but supplying at a negotiated price will also take care of the threat they face from compulsory licences whereby other ompanies are allowed to produce patented drugs in public interest.<br /><br />In past few years, several multinationals in India had to face a threat of compulsory licence after generic drug manufacturers claimed that they can make patented oncology and anti-retroviral medicines available at much lower prices. In fact, the first, and so far the only one, compulsory licence granted in India to Natco Pharma was also for a kidney cancer drug Nexavar, originally from Bayer.<br /><br />The second application by BDR Pharma seeking CL was also for Bristol-Myers Squibb's cancer drug Dasatinib. Though it was rejected by the Patent Office, a fresh application was subsequently submitted to the Centre under Section 92 of the Patents Act, which allows such licences to be issued under cases of national emergency. A decision is yet to be taken on the application.<br /><br />The latest health ministry's proposal is likely to get a final shape by end of this year.<br /><br />Currently, the government regulates a total of 348 medicine formulations, prices of which are fixed by the National Pharmaceutical Pricing Authority. Companies are free to price all other medicines but with an annual increase of only up to 10%. In case of stents, there is no price control. The government negotiates prices only for those supplied under CGHS.<br /><br /></div>               </font>
        </td>
    </tr>
    <tr>
        <td>&nbsp;</td>
    </tr>

    <tr>
        <td height="50" style="border-top:1px solid #000; border-bottom:1px solid #000;padding-top:10px;">
            <form><input type="button" value=" Print this page "
                         onclick="window.print();return false;"/></form>
        </td>
    </tr>
</table></body>
</html>'

}
$reasonPhrase = 'OK'
header - [internal], line ??
Cake\Http\ResponseEmitter::emitStatusLine() - CORE/src/Http/ResponseEmitter.php, line 148
Cake\Http\ResponseEmitter::emit() - CORE/src/Http/ResponseEmitter.php, line 54
Cake\Http\Server::emit() - CORE/src/Http/Server.php, line 141
[main] - ROOT/webroot/index.php, line 39

Warning (2): Cannot modify header information - headers already sent by (output started at /home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Debugger.php:853) [CORE/src/Http/ResponseEmitter.php, line 181]
Code Context
                    $value

                ), $first);

                $first = false;
$response = object(Cake\Http\Response) {

	'status' => (int) 200,
	'contentType' => 'text/html',
	'headers' => [
		'Content-Type' => [
			[maximum depth reached]
		]
	],
	'file' => null,
	'fileRange' => [],
	'cookies' => object(Cake\Http\Cookie\CookieCollection) {},
	'cacheDirectives' => [],
	'body' => '<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN"
        "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml">
<head>
    <link rel="canonical" href="https://im4change.in/<pre class="cake-error"><a href="javascript:void(0);" onclick="document.getElementById('cakeErr67fe7e3ca7549-trace').style.display = (document.getElementById('cakeErr67fe7e3ca7549-trace').style.display == 'none' ? '' : 'none');"><b>Notice</b> (8)</a>: Undefined variable: urlPrefix [<b>APP/Template/Layout/printlayout.ctp</b>, line <b>8</b>]<div id="cakeErr67fe7e3ca7549-trace" class="cake-stack-trace" style="display: none;"><a href="javascript:void(0);" onclick="document.getElementById('cakeErr67fe7e3ca7549-code').style.display = (document.getElementById('cakeErr67fe7e3ca7549-code').style.display == 'none' ? '' : 'none')">Code</a> <a href="javascript:void(0);" onclick="document.getElementById('cakeErr67fe7e3ca7549-context').style.display = (document.getElementById('cakeErr67fe7e3ca7549-context').style.display == 'none' ? '' : 'none')">Context</a><pre id="cakeErr67fe7e3ca7549-code" class="cake-code-dump" style="display: none;"><code><span style="color: #000000"><span style="color: #0000BB"></span><span style="color: #007700">&lt;</span><span style="color: #0000BB">head</span><span style="color: #007700">&gt;
</span></span></code>
<span class="code-highlight"><code><span style="color: #000000">&nbsp;&nbsp;&nbsp;&nbsp;&lt;link&nbsp;rel="canonical"&nbsp;href="<span style="color: #0000BB">&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">Configure</span><span style="color: #007700">::</span><span style="color: #0000BB">read</span><span style="color: #007700">(</span><span style="color: #DD0000">'SITE_URL'</span><span style="color: #007700">);&nbsp;</span><span style="color: #0000BB">?&gt;&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$urlPrefix</span><span style="color: #007700">;</span><span style="color: #0000BB">?&gt;&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$article_current</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">category</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">slug</span><span style="color: #007700">;&nbsp;</span><span style="color: #0000BB">?&gt;</span>/<span style="color: #0000BB">&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$article_current</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">seo_url</span><span style="color: #007700">;&nbsp;</span><span style="color: #0000BB">?&gt;</span>.html"/&gt;
</span></code></span>
<code><span style="color: #000000"><span style="color: #0000BB">&nbsp;&nbsp;&nbsp;&nbsp;</span><span style="color: #007700">&lt;</span><span style="color: #0000BB">meta&nbsp;http</span><span style="color: #007700">-</span><span style="color: #0000BB">equiv</span><span style="color: #007700">=</span><span style="color: #DD0000">"Content-Type"&nbsp;</span><span style="color: #0000BB">content</span><span style="color: #007700">=</span><span style="color: #DD0000">"text/html;&nbsp;charset=utf-8"</span><span style="color: #007700">/&gt;
</span></span></code></pre><pre id="cakeErr67fe7e3ca7549-context" class="cake-context" style="display: none;">$viewFile = &#039;/home/brlfuser/public_html/src/Template/Layout/printlayout.ctp&#039;
$dataForView = [
	&#039;article_current&#039; =&gt; object(App\Model\Entity\Article) {

		&#039;id&#039; =&gt; (int) 29209,
		&#039;title&#039; =&gt; &#039;Soon, cancer medicines, stents to be cheaper -Sushmi Dey&#039;,
		&#039;subheading&#039; =&gt; &#039;&#039;,
		&#039;description&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;
-The Times of India&lt;br /&gt;
&lt;br /&gt;
&lt;em&gt;NEW DELHI: &lt;/em&gt;Cancer medicines and stents may soon be available at a substantially lower price. The health ministry is working on a model to procure such drugs in bulk at a negotiated price and supply them to hospitals and consumers through its own retail system like &#039;Jan Aushadhi&#039; stores. .&lt;br /&gt;
&lt;br /&gt;
The idea is to bring down prices of expensive cancer drugs and stents while not putting pressure on margins of companies, a health ministry official told TOI. The government is in talks with pharmaceutical companies to implement the scheme.&lt;br /&gt;
&lt;br /&gt;
Currently, prices of only 51 cancer medicines are capped or regulated by the government. However, several oncologists, public health experts and even institutes like Tata Memorial Cancer Hospital have advocated bringing in more cancer drugs under price control as these medicines are extremely expensive and often out of reach of majority of patients.&lt;br /&gt;
&lt;br /&gt;
Following this, the health ministry had planned to bring in more cancer drugs and high-end medical devices like stents directly under price regulation, which would have meant capping their prices. However, the proposal faced strong opposition from the department of pharmaceuticals, which raised concerns about already squeezing margins of manufacturers and a threat to introduction of new drugs in the country.&lt;br /&gt;
&lt;br /&gt;
After the feedback, the health ministry decided to extend CGHS kind of mechanism to cancer medicines and stents for other consumers also, the official said.&lt;br /&gt;
&lt;br /&gt;
The new proposal is also likely to work in favour of the industry as not only their margins will be protected through bulk supplies but supplying at a negotiated price will also take care of the threat they face from compulsory licences whereby other ompanies are allowed to produce patented drugs in public interest.&lt;br /&gt;
&lt;br /&gt;
In past few years, several multinationals in India had to face a threat of compulsory licence after generic drug manufacturers claimed that they can make patented oncology and anti-retroviral medicines available at much lower prices. In fact, the first, and so far the only one, compulsory licence granted in India to Natco Pharma was also for a kidney cancer drug Nexavar, originally from Bayer.&lt;br /&gt;
&lt;br /&gt;
The second application by BDR Pharma seeking CL was also for Bristol-Myers Squibb&#039;s cancer drug Dasatinib. Though it was rejected by the Patent Office, a fresh application was subsequently submitted to the Centre under Section 92 of the Patents Act, which allows such licences to be issued under cases of national emergency. A decision is yet to be taken on the application.&lt;br /&gt;
&lt;br /&gt;
The latest health ministry&#039;s proposal is likely to get a final shape by end of this year.&lt;br /&gt;
&lt;br /&gt;
Currently, the government regulates a total of 348 medicine formulations, prices of which are fixed by the National Pharmaceutical Pricing Authority. Companies are free to price all other medicines but with an annual increase of only up to 10%. In case of stents, there is no price control. The government negotiates prices only for those supplied under CGHS.&lt;br /&gt;
&lt;br /&gt;
&lt;/div&gt;&#039;,
		&#039;credit_writer&#039; =&gt; &#039;The Times of India, 19 September, 2015, http://timesofindia.indiatimes.com/india/Soon-cancer-medicines-stents-to-be-cheaper/articleshow/49019942.cms&#039;,
		&#039;article_img&#039; =&gt; &#039;&#039;,
		&#039;article_img_thumb&#039; =&gt; &#039;&#039;,
		&#039;status&#039; =&gt; (int) 1,
		&#039;show_on_home&#039; =&gt; (int) 1,
		&#039;lang&#039; =&gt; &#039;EN&#039;,
		&#039;category_id&#039; =&gt; (int) 16,
		&#039;tag_keyword&#039; =&gt; &#039;&#039;,
		&#039;seo_url&#039; =&gt; &#039;soon-cancer-medicines-stents-to-be-cheaper-sushmi-dey-4677264&#039;,
		&#039;meta_title&#039; =&gt; null,
		&#039;meta_keywords&#039; =&gt; null,
		&#039;meta_description&#039; =&gt; null,
		&#039;noindex&#039; =&gt; (int) 0,
		&#039;publish_date&#039; =&gt; object(Cake\I18n\FrozenDate) {},
		&#039;most_visit_section_id&#039; =&gt; null,
		&#039;article_big_img&#039; =&gt; null,
		&#039;liveid&#039; =&gt; (int) 4677264,
		&#039;created&#039; =&gt; object(Cake\I18n\FrozenTime) {},
		&#039;modified&#039; =&gt; object(Cake\I18n\FrozenTime) {},
		&#039;edate&#039; =&gt; &#039;&#039;,
		&#039;tags&#039; =&gt; [
			[maximum depth reached]
		],
		&#039;category&#039; =&gt; object(App\Model\Entity\Category) {},
		&#039;[new]&#039; =&gt; false,
		&#039;[accessible]&#039; =&gt; [
			[maximum depth reached]
		],
		&#039;[dirty]&#039; =&gt; [[maximum depth reached]],
		&#039;[original]&#039; =&gt; [[maximum depth reached]],
		&#039;[virtual]&#039; =&gt; [[maximum depth reached]],
		&#039;[hasErrors]&#039; =&gt; false,
		&#039;[errors]&#039; =&gt; [[maximum depth reached]],
		&#039;[invalid]&#039; =&gt; [[maximum depth reached]],
		&#039;[repository]&#039; =&gt; &#039;Articles&#039;
	
	},
	&#039;articleid&#039; =&gt; (int) 29209,
	&#039;metaTitle&#039; =&gt; &#039;LATEST NEWS UPDATES | Soon, cancer medicines, stents to be cheaper -Sushmi Dey&#039;,
	&#039;metaKeywords&#039; =&gt; &#039;generic medicine,Compulsory license,Access to Health,Access to Healthcare,Access to Medicines,Cancer,medicines&#039;,
	&#039;metaDesc&#039; =&gt; &#039;
-The Times of India

NEW DELHI: Cancer medicines and stents may soon be available at a substantially lower price. The health ministry is working on a model to procure such drugs in bulk at a negotiated price and supply them to...&#039;,
	&#039;disp&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;-The Times of India&lt;br /&gt;&lt;br /&gt;&lt;em&gt;NEW DELHI: &lt;/em&gt;Cancer medicines and stents may soon be available at a substantially lower price. The health ministry is working on a model to procure such drugs in bulk at a negotiated price and supply them to hospitals and consumers through its own retail system like &#039;Jan Aushadhi&#039; stores. .&lt;br /&gt;&lt;br /&gt;The idea is to bring down prices of expensive cancer drugs and stents while not putting pressure on margins of companies, a health ministry official told TOI. The government is in talks with pharmaceutical companies to implement the scheme.&lt;br /&gt;&lt;br /&gt;Currently, prices of only 51 cancer medicines are capped or regulated by the government. However, several oncologists, public health experts and even institutes like Tata Memorial Cancer Hospital have advocated bringing in more cancer drugs under price control as these medicines are extremely expensive and often out of reach of majority of patients.&lt;br /&gt;&lt;br /&gt;Following this, the health ministry had planned to bring in more cancer drugs and high-end medical devices like stents directly under price regulation, which would have meant capping their prices. However, the proposal faced strong opposition from the department of pharmaceuticals, which raised concerns about already squeezing margins of manufacturers and a threat to introduction of new drugs in the country.&lt;br /&gt;&lt;br /&gt;After the feedback, the health ministry decided to extend CGHS kind of mechanism to cancer medicines and stents for other consumers also, the official said.&lt;br /&gt;&lt;br /&gt;The new proposal is also likely to work in favour of the industry as not only their margins will be protected through bulk supplies but supplying at a negotiated price will also take care of the threat they face from compulsory licences whereby other ompanies are allowed to produce patented drugs in public interest.&lt;br /&gt;&lt;br /&gt;In past few years, several multinationals in India had to face a threat of compulsory licence after generic drug manufacturers claimed that they can make patented oncology and anti-retroviral medicines available at much lower prices. In fact, the first, and so far the only one, compulsory licence granted in India to Natco Pharma was also for a kidney cancer drug Nexavar, originally from Bayer.&lt;br /&gt;&lt;br /&gt;The second application by BDR Pharma seeking CL was also for Bristol-Myers Squibb&#039;s cancer drug Dasatinib. Though it was rejected by the Patent Office, a fresh application was subsequently submitted to the Centre under Section 92 of the Patents Act, which allows such licences to be issued under cases of national emergency. A decision is yet to be taken on the application.&lt;br /&gt;&lt;br /&gt;The latest health ministry&#039;s proposal is likely to get a final shape by end of this year.&lt;br /&gt;&lt;br /&gt;Currently, the government regulates a total of 348 medicine formulations, prices of which are fixed by the National Pharmaceutical Pricing Authority. Companies are free to price all other medicines but with an annual increase of only up to 10%. In case of stents, there is no price control. The government negotiates prices only for those supplied under CGHS.&lt;br /&gt;&lt;br /&gt;&lt;/div&gt;&#039;,
	&#039;lang&#039; =&gt; &#039;English&#039;,
	&#039;SITE_URL&#039; =&gt; &#039;https://im4change.in/&#039;,
	&#039;site_title&#039; =&gt; &#039;im4change&#039;,
	&#039;adminprix&#039; =&gt; &#039;admin&#039;
]
$article_current = object(App\Model\Entity\Article) {

	&#039;id&#039; =&gt; (int) 29209,
	&#039;title&#039; =&gt; &#039;Soon, cancer medicines, stents to be cheaper -Sushmi Dey&#039;,
	&#039;subheading&#039; =&gt; &#039;&#039;,
	&#039;description&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;
-The Times of India&lt;br /&gt;
&lt;br /&gt;
&lt;em&gt;NEW DELHI: &lt;/em&gt;Cancer medicines and stents may soon be available at a substantially lower price. The health ministry is working on a model to procure such drugs in bulk at a negotiated price and supply them to hospitals and consumers through its own retail system like &#039;Jan Aushadhi&#039; stores. .&lt;br /&gt;
&lt;br /&gt;
The idea is to bring down prices of expensive cancer drugs and stents while not putting pressure on margins of companies, a health ministry official told TOI. The government is in talks with pharmaceutical companies to implement the scheme.&lt;br /&gt;
&lt;br /&gt;
Currently, prices of only 51 cancer medicines are capped or regulated by the government. However, several oncologists, public health experts and even institutes like Tata Memorial Cancer Hospital have advocated bringing in more cancer drugs under price control as these medicines are extremely expensive and often out of reach of majority of patients.&lt;br /&gt;
&lt;br /&gt;
Following this, the health ministry had planned to bring in more cancer drugs and high-end medical devices like stents directly under price regulation, which would have meant capping their prices. However, the proposal faced strong opposition from the department of pharmaceuticals, which raised concerns about already squeezing margins of manufacturers and a threat to introduction of new drugs in the country.&lt;br /&gt;
&lt;br /&gt;
After the feedback, the health ministry decided to extend CGHS kind of mechanism to cancer medicines and stents for other consumers also, the official said.&lt;br /&gt;
&lt;br /&gt;
The new proposal is also likely to work in favour of the industry as not only their margins will be protected through bulk supplies but supplying at a negotiated price will also take care of the threat they face from compulsory licences whereby other ompanies are allowed to produce patented drugs in public interest.&lt;br /&gt;
&lt;br /&gt;
In past few years, several multinationals in India had to face a threat of compulsory licence after generic drug manufacturers claimed that they can make patented oncology and anti-retroviral medicines available at much lower prices. In fact, the first, and so far the only one, compulsory licence granted in India to Natco Pharma was also for a kidney cancer drug Nexavar, originally from Bayer.&lt;br /&gt;
&lt;br /&gt;
The second application by BDR Pharma seeking CL was also for Bristol-Myers Squibb&#039;s cancer drug Dasatinib. Though it was rejected by the Patent Office, a fresh application was subsequently submitted to the Centre under Section 92 of the Patents Act, which allows such licences to be issued under cases of national emergency. A decision is yet to be taken on the application.&lt;br /&gt;
&lt;br /&gt;
The latest health ministry&#039;s proposal is likely to get a final shape by end of this year.&lt;br /&gt;
&lt;br /&gt;
Currently, the government regulates a total of 348 medicine formulations, prices of which are fixed by the National Pharmaceutical Pricing Authority. Companies are free to price all other medicines but with an annual increase of only up to 10%. In case of stents, there is no price control. The government negotiates prices only for those supplied under CGHS.&lt;br /&gt;
&lt;br /&gt;
&lt;/div&gt;&#039;,
	&#039;credit_writer&#039; =&gt; &#039;The Times of India, 19 September, 2015, http://timesofindia.indiatimes.com/india/Soon-cancer-medicines-stents-to-be-cheaper/articleshow/49019942.cms&#039;,
	&#039;article_img&#039; =&gt; &#039;&#039;,
	&#039;article_img_thumb&#039; =&gt; &#039;&#039;,
	&#039;status&#039; =&gt; (int) 1,
	&#039;show_on_home&#039; =&gt; (int) 1,
	&#039;lang&#039; =&gt; &#039;EN&#039;,
	&#039;category_id&#039; =&gt; (int) 16,
	&#039;tag_keyword&#039; =&gt; &#039;&#039;,
	&#039;seo_url&#039; =&gt; &#039;soon-cancer-medicines-stents-to-be-cheaper-sushmi-dey-4677264&#039;,
	&#039;meta_title&#039; =&gt; null,
	&#039;meta_keywords&#039; =&gt; null,
	&#039;meta_description&#039; =&gt; null,
	&#039;noindex&#039; =&gt; (int) 0,
	&#039;publish_date&#039; =&gt; object(Cake\I18n\FrozenDate) {},
	&#039;most_visit_section_id&#039; =&gt; null,
	&#039;article_big_img&#039; =&gt; null,
	&#039;liveid&#039; =&gt; (int) 4677264,
	&#039;created&#039; =&gt; object(Cake\I18n\FrozenTime) {},
	&#039;modified&#039; =&gt; object(Cake\I18n\FrozenTime) {},
	&#039;edate&#039; =&gt; &#039;&#039;,
	&#039;tags&#039; =&gt; [
		(int) 0 =&gt; object(Cake\ORM\Entity) {},
		(int) 1 =&gt; object(Cake\ORM\Entity) {},
		(int) 2 =&gt; object(Cake\ORM\Entity) {},
		(int) 3 =&gt; object(Cake\ORM\Entity) {},
		(int) 4 =&gt; object(Cake\ORM\Entity) {},
		(int) 5 =&gt; object(Cake\ORM\Entity) {},
		(int) 6 =&gt; object(Cake\ORM\Entity) {}
	],
	&#039;category&#039; =&gt; object(App\Model\Entity\Category) {},
	&#039;[new]&#039; =&gt; false,
	&#039;[accessible]&#039; =&gt; [
		&#039;*&#039; =&gt; true,
		&#039;id&#039; =&gt; false
	],
	&#039;[dirty]&#039; =&gt; [],
	&#039;[original]&#039; =&gt; [],
	&#039;[virtual]&#039; =&gt; [],
	&#039;[hasErrors]&#039; =&gt; false,
	&#039;[errors]&#039; =&gt; [],
	&#039;[invalid]&#039; =&gt; [],
	&#039;[repository]&#039; =&gt; &#039;Articles&#039;

}
$articleid = (int) 29209
$metaTitle = &#039;LATEST NEWS UPDATES | Soon, cancer medicines, stents to be cheaper -Sushmi Dey&#039;
$metaKeywords = &#039;generic medicine,Compulsory license,Access to Health,Access to Healthcare,Access to Medicines,Cancer,medicines&#039;
$metaDesc = &#039;
-The Times of India

NEW DELHI: Cancer medicines and stents may soon be available at a substantially lower price. The health ministry is working on a model to procure such drugs in bulk at a negotiated price and supply them to...&#039;
$disp = &#039;&lt;div align=&quot;justify&quot;&gt;-The Times of India&lt;br /&gt;&lt;br /&gt;&lt;em&gt;NEW DELHI: &lt;/em&gt;Cancer medicines and stents may soon be available at a substantially lower price. The health ministry is working on a model to procure such drugs in bulk at a negotiated price and supply them to hospitals and consumers through its own retail system like &#039;Jan Aushadhi&#039; stores. .&lt;br /&gt;&lt;br /&gt;The idea is to bring down prices of expensive cancer drugs and stents while not putting pressure on margins of companies, a health ministry official told TOI. The government is in talks with pharmaceutical companies to implement the scheme.&lt;br /&gt;&lt;br /&gt;Currently, prices of only 51 cancer medicines are capped or regulated by the government. However, several oncologists, public health experts and even institutes like Tata Memorial Cancer Hospital have advocated bringing in more cancer drugs under price control as these medicines are extremely expensive and often out of reach of majority of patients.&lt;br /&gt;&lt;br /&gt;Following this, the health ministry had planned to bring in more cancer drugs and high-end medical devices like stents directly under price regulation, which would have meant capping their prices. However, the proposal faced strong opposition from the department of pharmaceuticals, which raised concerns about already squeezing margins of manufacturers and a threat to introduction of new drugs in the country.&lt;br /&gt;&lt;br /&gt;After the feedback, the health ministry decided to extend CGHS kind of mechanism to cancer medicines and stents for other consumers also, the official said.&lt;br /&gt;&lt;br /&gt;The new proposal is also likely to work in favour of the industry as not only their margins will be protected through bulk supplies but supplying at a negotiated price will also take care of the threat they face from compulsory licences whereby other ompanies are allowed to produce patented drugs in public interest.&lt;br /&gt;&lt;br /&gt;In past few years, several multinationals in India had to face a threat of compulsory licence after generic drug manufacturers claimed that they can make patented oncology and anti-retroviral medicines available at much lower prices. In fact, the first, and so far the only one, compulsory licence granted in India to Natco Pharma was also for a kidney cancer drug Nexavar, originally from Bayer.&lt;br /&gt;&lt;br /&gt;The second application by BDR Pharma seeking CL was also for Bristol-Myers Squibb&#039;s cancer drug Dasatinib. Though it was rejected by the Patent Office, a fresh application was subsequently submitted to the Centre under Section 92 of the Patents Act, which allows such licences to be issued under cases of national emergency. A decision is yet to be taken on the application.&lt;br /&gt;&lt;br /&gt;The latest health ministry&#039;s proposal is likely to get a final shape by end of this year.&lt;br /&gt;&lt;br /&gt;Currently, the government regulates a total of 348 medicine formulations, prices of which are fixed by the National Pharmaceutical Pricing Authority. Companies are free to price all other medicines but with an annual increase of only up to 10%. In case of stents, there is no price control. The government negotiates prices only for those supplied under CGHS.&lt;br /&gt;&lt;br /&gt;&lt;/div&gt;&#039;
$lang = &#039;English&#039;
$SITE_URL = &#039;https://im4change.in/&#039;
$site_title = &#039;im4change&#039;
$adminprix = &#039;admin&#039;</pre><pre class="stack-trace">include - APP/Template/Layout/printlayout.ctp, line 8
Cake\View\View::_evaluate() - CORE/src/View/View.php, line 1413
Cake\View\View::_render() - CORE/src/View/View.php, line 1374
Cake\View\View::renderLayout() - CORE/src/View/View.php, line 927
Cake\View\View::render() - CORE/src/View/View.php, line 885
Cake\Controller\Controller::render() - CORE/src/Controller/Controller.php, line 791
Cake\Http\ActionDispatcher::_invoke() - CORE/src/Http/ActionDispatcher.php, line 126
Cake\Http\ActionDispatcher::dispatch() - CORE/src/Http/ActionDispatcher.php, line 94
Cake\Http\BaseApplication::__invoke() - CORE/src/Http/BaseApplication.php, line 235
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\RoutingMiddleware::__invoke() - CORE/src/Routing/Middleware/RoutingMiddleware.php, line 162
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\AssetMiddleware::__invoke() - CORE/src/Routing/Middleware/AssetMiddleware.php, line 88
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Error\Middleware\ErrorHandlerMiddleware::__invoke() - CORE/src/Error/Middleware/ErrorHandlerMiddleware.php, line 96
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Http\Runner::run() - CORE/src/Http/Runner.php, line 51</pre></div></pre>latest-news-updates/soon-cancer-medicines-stents-to-be-cheaper-sushmi-dey-4677264.html"/>
    <meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>
    <link href="https://im4change.in/css/control.css" rel="stylesheet" type="text/css"
          media="all"/>
    <title>LATEST NEWS UPDATES | Soon, cancer medicines, stents to be cheaper -Sushmi Dey | Im4change.org</title>
    <meta name="description" content="
-The Times of India

NEW DELHI: Cancer medicines and stents may soon be available at a substantially lower price. The health ministry is working on a model to procure such drugs in bulk at a negotiated price and supply them to..."/>
    <script src="https://im4change.in/js/jquery-1.10.2.js"></script>
    <script type="text/javascript" src="https://im4change.in/js/jquery-migrate.min.js"></script>
    <script language="javascript" type="text/javascript">

        $(document).ready(function () {
            var img = $("img")[0]; // Get my img elem
            var pic_real_width, pic_real_height;
            $("<img/>") // Make in memory copy of image to avoid css issues
                .attr("src", $(img).attr("src"))
                .load(function () {
                    pic_real_width = this.width;   // Note: $(this).width() will not
                    pic_real_height = this.height; // work for in memory images.
                });
        });
    </script>
    <style type="text/css">
        @media screen {
            div.divFooter {
                display: block;
            }
        }

        @media print {
            .printbutton {
                display: none !important;
            }
        }
    </style>
</head>
<body>
<table cellpadding="0" cellspacing="0" border="0" width="98%" align="center">
    <tr>
        <td class="top_bg">
            <div class="divFooter">
                <img src="https://im4change.in/images/logo1.jpg" height="59" border="0"
                     alt="Resource centre on India's rural distress" style="padding-top:14px;"/>
            </div>

        </td>
    </tr>
    <tr>
        <td id="topspace">&nbsp;</td>
    </tr>

    <tr id="topspace">
        <td>&nbsp;</td>
    </tr>
    <tr>
        <td height="50" style="border-bottom:1px solid #000; padding-top:10px;" class="printbutton">
            <form><input type="button" value=" Print this page "
                         onclick="window.print();return false;"/></form>
        </td>
    </tr>

    <tr>
        <td width="100%">
            <h1 class="news_headlines" style="font-style:normal">
                <strong>Soon, cancer medicines, stents to be cheaper -Sushmi Dey</strong></h1>
        </td>
    </tr>
    <tr>
        <td width="100%" style="font-family:Arial, 'Segoe Script', 'Segoe UI', sans-serif, serif"><font size="3">
                <div align="justify">-The Times of India<br /><br /><em>NEW DELHI: </em>Cancer medicines and stents may soon be available at a substantially lower price. The health ministry is working on a model to procure such drugs in bulk at a negotiated price and supply them to hospitals and consumers through its own retail system like 'Jan Aushadhi' stores. .<br /><br />The idea is to bring down prices of expensive cancer drugs and stents while not putting pressure on margins of companies, a health ministry official told TOI. The government is in talks with pharmaceutical companies to implement the scheme.<br /><br />Currently, prices of only 51 cancer medicines are capped or regulated by the government. However, several oncologists, public health experts and even institutes like Tata Memorial Cancer Hospital have advocated bringing in more cancer drugs under price control as these medicines are extremely expensive and often out of reach of majority of patients.<br /><br />Following this, the health ministry had planned to bring in more cancer drugs and high-end medical devices like stents directly under price regulation, which would have meant capping their prices. However, the proposal faced strong opposition from the department of pharmaceuticals, which raised concerns about already squeezing margins of manufacturers and a threat to introduction of new drugs in the country.<br /><br />After the feedback, the health ministry decided to extend CGHS kind of mechanism to cancer medicines and stents for other consumers also, the official said.<br /><br />The new proposal is also likely to work in favour of the industry as not only their margins will be protected through bulk supplies but supplying at a negotiated price will also take care of the threat they face from compulsory licences whereby other ompanies are allowed to produce patented drugs in public interest.<br /><br />In past few years, several multinationals in India had to face a threat of compulsory licence after generic drug manufacturers claimed that they can make patented oncology and anti-retroviral medicines available at much lower prices. In fact, the first, and so far the only one, compulsory licence granted in India to Natco Pharma was also for a kidney cancer drug Nexavar, originally from Bayer.<br /><br />The second application by BDR Pharma seeking CL was also for Bristol-Myers Squibb's cancer drug Dasatinib. Though it was rejected by the Patent Office, a fresh application was subsequently submitted to the Centre under Section 92 of the Patents Act, which allows such licences to be issued under cases of national emergency. A decision is yet to be taken on the application.<br /><br />The latest health ministry's proposal is likely to get a final shape by end of this year.<br /><br />Currently, the government regulates a total of 348 medicine formulations, prices of which are fixed by the National Pharmaceutical Pricing Authority. Companies are free to price all other medicines but with an annual increase of only up to 10%. In case of stents, there is no price control. The government negotiates prices only for those supplied under CGHS.<br /><br /></div>               </font>
        </td>
    </tr>
    <tr>
        <td>&nbsp;</td>
    </tr>

    <tr>
        <td height="50" style="border-top:1px solid #000; border-bottom:1px solid #000;padding-top:10px;">
            <form><input type="button" value=" Print this page "
                         onclick="window.print();return false;"/></form>
        </td>
    </tr>
</table></body>
</html>'

}
$cookies = []
$values = [
	(int) 0 => 'text/html; charset=UTF-8'
]
$name = 'Content-Type'
$first = true
$value = 'text/html; charset=UTF-8'
header - [internal], line ??
Cake\Http\ResponseEmitter::emitHeaders() - CORE/src/Http/ResponseEmitter.php, line 181
Cake\Http\ResponseEmitter::emit() - CORE/src/Http/ResponseEmitter.php, line 55
Cake\Http\Server::emit() - CORE/src/Http/Server.php, line 141
[main] - ROOT/webroot/index.php, line 39

<head>

    <link rel="canonical" href="<?php echo Configure::read('SITE_URL'); ?><?php echo $urlPrefix;?><?php echo $article_current->category->slug; ?>/<?php echo $article_current->seo_url; ?>.html"/>

    <meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>

$viewFile = '/home/brlfuser/public_html/src/Template/Layout/printlayout.ctp'
$dataForView = [
	'article_current' => object(App\Model\Entity\Article) {

		'id' => (int) 29209,
		'title' => 'Soon, cancer medicines, stents to be cheaper -Sushmi Dey',
		'subheading' => '',
		'description' => '<div align="justify">
-The Times of India<br />
<br />
<em>NEW DELHI: </em>Cancer medicines and stents may soon be available at a substantially lower price. The health ministry is working on a model to procure such drugs in bulk at a negotiated price and supply them to hospitals and consumers through its own retail system like 'Jan Aushadhi' stores. .<br />
<br />
The idea is to bring down prices of expensive cancer drugs and stents while not putting pressure on margins of companies, a health ministry official told TOI. The government is in talks with pharmaceutical companies to implement the scheme.<br />
<br />
Currently, prices of only 51 cancer medicines are capped or regulated by the government. However, several oncologists, public health experts and even institutes like Tata Memorial Cancer Hospital have advocated bringing in more cancer drugs under price control as these medicines are extremely expensive and often out of reach of majority of patients.<br />
<br />
Following this, the health ministry had planned to bring in more cancer drugs and high-end medical devices like stents directly under price regulation, which would have meant capping their prices. However, the proposal faced strong opposition from the department of pharmaceuticals, which raised concerns about already squeezing margins of manufacturers and a threat to introduction of new drugs in the country.<br />
<br />
After the feedback, the health ministry decided to extend CGHS kind of mechanism to cancer medicines and stents for other consumers also, the official said.<br />
<br />
The new proposal is also likely to work in favour of the industry as not only their margins will be protected through bulk supplies but supplying at a negotiated price will also take care of the threat they face from compulsory licences whereby other ompanies are allowed to produce patented drugs in public interest.<br />
<br />
In past few years, several multinationals in India had to face a threat of compulsory licence after generic drug manufacturers claimed that they can make patented oncology and anti-retroviral medicines available at much lower prices. In fact, the first, and so far the only one, compulsory licence granted in India to Natco Pharma was also for a kidney cancer drug Nexavar, originally from Bayer.<br />
<br />
The second application by BDR Pharma seeking CL was also for Bristol-Myers Squibb's cancer drug Dasatinib. Though it was rejected by the Patent Office, a fresh application was subsequently submitted to the Centre under Section 92 of the Patents Act, which allows such licences to be issued under cases of national emergency. A decision is yet to be taken on the application.<br />
<br />
The latest health ministry's proposal is likely to get a final shape by end of this year.<br />
<br />
Currently, the government regulates a total of 348 medicine formulations, prices of which are fixed by the National Pharmaceutical Pricing Authority. Companies are free to price all other medicines but with an annual increase of only up to 10%. In case of stents, there is no price control. The government negotiates prices only for those supplied under CGHS.<br />
<br />
</div>',
		'credit_writer' => 'The Times of India, 19 September, 2015, http://timesofindia.indiatimes.com/india/Soon-cancer-medicines-stents-to-be-cheaper/articleshow/49019942.cms',
		'article_img' => '',
		'article_img_thumb' => '',
		'status' => (int) 1,
		'show_on_home' => (int) 1,
		'lang' => 'EN',
		'category_id' => (int) 16,
		'tag_keyword' => '',
		'seo_url' => 'soon-cancer-medicines-stents-to-be-cheaper-sushmi-dey-4677264',
		'meta_title' => null,
		'meta_keywords' => null,
		'meta_description' => null,
		'noindex' => (int) 0,
		'publish_date' => object(Cake\I18n\FrozenDate) {},
		'most_visit_section_id' => null,
		'article_big_img' => null,
		'liveid' => (int) 4677264,
		'created' => object(Cake\I18n\FrozenTime) {},
		'modified' => object(Cake\I18n\FrozenTime) {},
		'edate' => '',
		'tags' => [
			[maximum depth reached]
		],
		'category' => object(App\Model\Entity\Category) {},
		'[new]' => false,
		'[accessible]' => [
			[maximum depth reached]
		],
		'[dirty]' => [[maximum depth reached]],
		'[original]' => [[maximum depth reached]],
		'[virtual]' => [[maximum depth reached]],
		'[hasErrors]' => false,
		'[errors]' => [[maximum depth reached]],
		'[invalid]' => [[maximum depth reached]],
		'[repository]' => 'Articles'
	
	},
	'articleid' => (int) 29209,
	'metaTitle' => 'LATEST NEWS UPDATES | Soon, cancer medicines, stents to be cheaper -Sushmi Dey',
	'metaKeywords' => 'generic medicine,Compulsory license,Access to Health,Access to Healthcare,Access to Medicines,Cancer,medicines',
	'metaDesc' => '
-The Times of India

NEW DELHI: Cancer medicines and stents may soon be available at a substantially lower price. The health ministry is working on a model to procure such drugs in bulk at a negotiated price and supply them to...',
	'disp' => '<div align="justify">-The Times of India<br /><br /><em>NEW DELHI: </em>Cancer medicines and stents may soon be available at a substantially lower price. The health ministry is working on a model to procure such drugs in bulk at a negotiated price and supply them to hospitals and consumers through its own retail system like 'Jan Aushadhi' stores. .<br /><br />The idea is to bring down prices of expensive cancer drugs and stents while not putting pressure on margins of companies, a health ministry official told TOI. The government is in talks with pharmaceutical companies to implement the scheme.<br /><br />Currently, prices of only 51 cancer medicines are capped or regulated by the government. However, several oncologists, public health experts and even institutes like Tata Memorial Cancer Hospital have advocated bringing in more cancer drugs under price control as these medicines are extremely expensive and often out of reach of majority of patients.<br /><br />Following this, the health ministry had planned to bring in more cancer drugs and high-end medical devices like stents directly under price regulation, which would have meant capping their prices. However, the proposal faced strong opposition from the department of pharmaceuticals, which raised concerns about already squeezing margins of manufacturers and a threat to introduction of new drugs in the country.<br /><br />After the feedback, the health ministry decided to extend CGHS kind of mechanism to cancer medicines and stents for other consumers also, the official said.<br /><br />The new proposal is also likely to work in favour of the industry as not only their margins will be protected through bulk supplies but supplying at a negotiated price will also take care of the threat they face from compulsory licences whereby other ompanies are allowed to produce patented drugs in public interest.<br /><br />In past few years, several multinationals in India had to face a threat of compulsory licence after generic drug manufacturers claimed that they can make patented oncology and anti-retroviral medicines available at much lower prices. In fact, the first, and so far the only one, compulsory licence granted in India to Natco Pharma was also for a kidney cancer drug Nexavar, originally from Bayer.<br /><br />The second application by BDR Pharma seeking CL was also for Bristol-Myers Squibb's cancer drug Dasatinib. Though it was rejected by the Patent Office, a fresh application was subsequently submitted to the Centre under Section 92 of the Patents Act, which allows such licences to be issued under cases of national emergency. A decision is yet to be taken on the application.<br /><br />The latest health ministry's proposal is likely to get a final shape by end of this year.<br /><br />Currently, the government regulates a total of 348 medicine formulations, prices of which are fixed by the National Pharmaceutical Pricing Authority. Companies are free to price all other medicines but with an annual increase of only up to 10%. In case of stents, there is no price control. The government negotiates prices only for those supplied under CGHS.<br /><br /></div>',
	'lang' => 'English',
	'SITE_URL' => 'https://im4change.in/',
	'site_title' => 'im4change',
	'adminprix' => 'admin'
]
$article_current = object(App\Model\Entity\Article) {

	'id' => (int) 29209,
	'title' => 'Soon, cancer medicines, stents to be cheaper -Sushmi Dey',
	'subheading' => '',
	'description' => '<div align="justify">
-The Times of India<br />
<br />
<em>NEW DELHI: </em>Cancer medicines and stents may soon be available at a substantially lower price. The health ministry is working on a model to procure such drugs in bulk at a negotiated price and supply them to hospitals and consumers through its own retail system like 'Jan Aushadhi' stores. .<br />
<br />
The idea is to bring down prices of expensive cancer drugs and stents while not putting pressure on margins of companies, a health ministry official told TOI. The government is in talks with pharmaceutical companies to implement the scheme.<br />
<br />
Currently, prices of only 51 cancer medicines are capped or regulated by the government. However, several oncologists, public health experts and even institutes like Tata Memorial Cancer Hospital have advocated bringing in more cancer drugs under price control as these medicines are extremely expensive and often out of reach of majority of patients.<br />
<br />
Following this, the health ministry had planned to bring in more cancer drugs and high-end medical devices like stents directly under price regulation, which would have meant capping their prices. However, the proposal faced strong opposition from the department of pharmaceuticals, which raised concerns about already squeezing margins of manufacturers and a threat to introduction of new drugs in the country.<br />
<br />
After the feedback, the health ministry decided to extend CGHS kind of mechanism to cancer medicines and stents for other consumers also, the official said.<br />
<br />
The new proposal is also likely to work in favour of the industry as not only their margins will be protected through bulk supplies but supplying at a negotiated price will also take care of the threat they face from compulsory licences whereby other ompanies are allowed to produce patented drugs in public interest.<br />
<br />
In past few years, several multinationals in India had to face a threat of compulsory licence after generic drug manufacturers claimed that they can make patented oncology and anti-retroviral medicines available at much lower prices. In fact, the first, and so far the only one, compulsory licence granted in India to Natco Pharma was also for a kidney cancer drug Nexavar, originally from Bayer.<br />
<br />
The second application by BDR Pharma seeking CL was also for Bristol-Myers Squibb's cancer drug Dasatinib. Though it was rejected by the Patent Office, a fresh application was subsequently submitted to the Centre under Section 92 of the Patents Act, which allows such licences to be issued under cases of national emergency. A decision is yet to be taken on the application.<br />
<br />
The latest health ministry's proposal is likely to get a final shape by end of this year.<br />
<br />
Currently, the government regulates a total of 348 medicine formulations, prices of which are fixed by the National Pharmaceutical Pricing Authority. Companies are free to price all other medicines but with an annual increase of only up to 10%. In case of stents, there is no price control. The government negotiates prices only for those supplied under CGHS.<br />
<br />
</div>',
	'credit_writer' => 'The Times of India, 19 September, 2015, http://timesofindia.indiatimes.com/india/Soon-cancer-medicines-stents-to-be-cheaper/articleshow/49019942.cms',
	'article_img' => '',
	'article_img_thumb' => '',
	'status' => (int) 1,
	'show_on_home' => (int) 1,
	'lang' => 'EN',
	'category_id' => (int) 16,
	'tag_keyword' => '',
	'seo_url' => 'soon-cancer-medicines-stents-to-be-cheaper-sushmi-dey-4677264',
	'meta_title' => null,
	'meta_keywords' => null,
	'meta_description' => null,
	'noindex' => (int) 0,
	'publish_date' => object(Cake\I18n\FrozenDate) {},
	'most_visit_section_id' => null,
	'article_big_img' => null,
	'liveid' => (int) 4677264,
	'created' => object(Cake\I18n\FrozenTime) {},
	'modified' => object(Cake\I18n\FrozenTime) {},
	'edate' => '',
	'tags' => [
		(int) 0 => object(Cake\ORM\Entity) {},
		(int) 1 => object(Cake\ORM\Entity) {},
		(int) 2 => object(Cake\ORM\Entity) {},
		(int) 3 => object(Cake\ORM\Entity) {},
		(int) 4 => object(Cake\ORM\Entity) {},
		(int) 5 => object(Cake\ORM\Entity) {},
		(int) 6 => object(Cake\ORM\Entity) {}
	],
	'category' => object(App\Model\Entity\Category) {},
	'[new]' => false,
	'[accessible]' => [
		'*' => true,
		'id' => false
	],
	'[dirty]' => [],
	'[original]' => [],
	'[virtual]' => [],
	'[hasErrors]' => false,
	'[errors]' => [],
	'[invalid]' => [],
	'[repository]' => 'Articles'

}
$articleid = (int) 29209
$metaTitle = 'LATEST NEWS UPDATES | Soon, cancer medicines, stents to be cheaper -Sushmi Dey'
$metaKeywords = 'generic medicine,Compulsory license,Access to Health,Access to Healthcare,Access to Medicines,Cancer,medicines'
$metaDesc = '
-The Times of India

NEW DELHI: Cancer medicines and stents may soon be available at a substantially lower price. The health ministry is working on a model to procure such drugs in bulk at a negotiated price and supply them to...'
$disp = '<div align="justify">-The Times of India<br /><br /><em>NEW DELHI: </em>Cancer medicines and stents may soon be available at a substantially lower price. The health ministry is working on a model to procure such drugs in bulk at a negotiated price and supply them to hospitals and consumers through its own retail system like 'Jan Aushadhi' stores. .<br /><br />The idea is to bring down prices of expensive cancer drugs and stents while not putting pressure on margins of companies, a health ministry official told TOI. The government is in talks with pharmaceutical companies to implement the scheme.<br /><br />Currently, prices of only 51 cancer medicines are capped or regulated by the government. However, several oncologists, public health experts and even institutes like Tata Memorial Cancer Hospital have advocated bringing in more cancer drugs under price control as these medicines are extremely expensive and often out of reach of majority of patients.<br /><br />Following this, the health ministry had planned to bring in more cancer drugs and high-end medical devices like stents directly under price regulation, which would have meant capping their prices. However, the proposal faced strong opposition from the department of pharmaceuticals, which raised concerns about already squeezing margins of manufacturers and a threat to introduction of new drugs in the country.<br /><br />After the feedback, the health ministry decided to extend CGHS kind of mechanism to cancer medicines and stents for other consumers also, the official said.<br /><br />The new proposal is also likely to work in favour of the industry as not only their margins will be protected through bulk supplies but supplying at a negotiated price will also take care of the threat they face from compulsory licences whereby other ompanies are allowed to produce patented drugs in public interest.<br /><br />In past few years, several multinationals in India had to face a threat of compulsory licence after generic drug manufacturers claimed that they can make patented oncology and anti-retroviral medicines available at much lower prices. In fact, the first, and so far the only one, compulsory licence granted in India to Natco Pharma was also for a kidney cancer drug Nexavar, originally from Bayer.<br /><br />The second application by BDR Pharma seeking CL was also for Bristol-Myers Squibb's cancer drug Dasatinib. Though it was rejected by the Patent Office, a fresh application was subsequently submitted to the Centre under Section 92 of the Patents Act, which allows such licences to be issued under cases of national emergency. A decision is yet to be taken on the application.<br /><br />The latest health ministry's proposal is likely to get a final shape by end of this year.<br /><br />Currently, the government regulates a total of 348 medicine formulations, prices of which are fixed by the National Pharmaceutical Pricing Authority. Companies are free to price all other medicines but with an annual increase of only up to 10%. In case of stents, there is no price control. The government negotiates prices only for those supplied under CGHS.<br /><br /></div>'
$lang = 'English'
$SITE_URL = 'https://im4change.in/'
$site_title = 'im4change'
$adminprix = 'admin'

include - APP/Template/Layout/printlayout.ctp, line 8
Cake\View\View::_evaluate() - CORE/src/View/View.php, line 1413
Cake\View\View::_render() - CORE/src/View/View.php, line 1374
Cake\View\View::renderLayout() - CORE/src/View/View.php, line 927
Cake\View\View::render() - CORE/src/View/View.php, line 885
Cake\Controller\Controller::render() - CORE/src/Controller/Controller.php, line 791
Cake\Http\ActionDispatcher::_invoke() - CORE/src/Http/ActionDispatcher.php, line 126
Cake\Http\ActionDispatcher::dispatch() - CORE/src/Http/ActionDispatcher.php, line 94
Cake\Http\BaseApplication::__invoke() - CORE/src/Http/BaseApplication.php, line 235
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\RoutingMiddleware::__invoke() - CORE/src/Routing/Middleware/RoutingMiddleware.php, line 162
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\AssetMiddleware::__invoke() - CORE/src/Routing/Middleware/AssetMiddleware.php, line 88
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Error\Middleware\ErrorHandlerMiddleware::__invoke() - CORE/src/Error/Middleware/ErrorHandlerMiddleware.php, line 96
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Http\Runner::run() - CORE/src/Http/Runner.php, line 51

Soon, cancer medicines, stents to be cheaper -Sushmi Dey

-The Times of India NEW DELHI: Cancer medicines and stents may soon be available at a substantially lower price. The health ministry is working on a model to procure such drugs in bulk at a negotiated price and supply them to hospitals and consumers through its own retail system like 'Jan Aushadhi' stores. . The idea is to bring down prices of expensive cancer drugs and stents while not putting pressure on margins of companies, a health ministry official told TOI. The government is in talks with pharmaceutical companies to implement the scheme. Currently, prices of only 51 cancer medicines are capped or regulated by the government. However, several oncologists, public health experts and even institutes like Tata Memorial Cancer Hospital have advocated bringing in more cancer drugs under price control as these medicines are extremely expensive and often out of reach of majority of patients. Following this, the health ministry had planned to bring in more cancer drugs and high-end medical devices like stents directly under price regulation, which would have meant capping their prices. However, the proposal faced strong opposition from the department of pharmaceuticals, which raised concerns about already squeezing margins of manufacturers and a threat to introduction of new drugs in the country. After the feedback, the health ministry decided to extend CGHS kind of mechanism to cancer medicines and stents for other consumers also, the official said. The new proposal is also likely to work in favour of the industry as not only their margins will be protected through bulk supplies but supplying at a negotiated price will also take care of the threat they face from compulsory licences whereby other ompanies are allowed to produce patented drugs in public interest. In past few years, several multinationals in India had to face a threat of compulsory licence after generic drug manufacturers claimed that they can make patented oncology and anti-retroviral medicines available at much lower prices. In fact, the first, and so far the only one, compulsory licence granted in India to Natco Pharma was also for a kidney cancer drug Nexavar, originally from Bayer. The second application by BDR Pharma seeking CL was also for Bristol-Myers Squibb's cancer drug Dasatinib. Though it was rejected by the Patent Office, a fresh application was subsequently submitted to the Centre under Section 92 of the Patents Act, which allows such licences to be issued under cases of national emergency. A decision is yet to be taken on the application. The latest health ministry's proposal is likely to get a final shape by end of this year. Currently, the government regulates a total of 348 medicine formulations, prices of which are fixed by the National Pharmaceutical Pricing Authority. Companies are free to price all other medicines but with an annual increase of only up to 10%. In case of stents, there is no price control. The government negotiates prices only for those supplied under CGHS.